CN111253397A - Mnk抑制剂 - Google Patents
Mnk抑制剂 Download PDFInfo
- Publication number
- CN111253397A CN111253397A CN201911196669.1A CN201911196669A CN111253397A CN 111253397 A CN111253397 A CN 111253397A CN 201911196669 A CN201911196669 A CN 201911196669A CN 111253397 A CN111253397 A CN 111253397A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- formula
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 17
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 94
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims abstract description 32
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims abstract description 32
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims abstract description 23
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims abstract description 23
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 260
- -1 C2-6Alkenyl radical Chemical class 0.000 claims description 141
- 150000003254 radicals Chemical class 0.000 claims description 92
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 68
- 229910052736 halogen Inorganic materials 0.000 claims description 59
- 229940002612 prodrug Drugs 0.000 claims description 57
- 239000000651 prodrug Substances 0.000 claims description 57
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 56
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 53
- 238000006467 substitution reaction Methods 0.000 claims description 53
- 125000001424 substituent group Chemical group 0.000 claims description 51
- 150000002367 halogens Chemical class 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000005843 halogen group Chemical group 0.000 claims description 46
- 230000000155 isotopic effect Effects 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000000460 chlorine Substances 0.000 claims description 32
- 229910052801 chlorine Inorganic materials 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 22
- 229910052731 fluorine Inorganic materials 0.000 claims description 22
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 11
- 125000003003 spiro group Chemical group 0.000 claims description 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 10
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 7
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 177
- 230000015572 biosynthetic process Effects 0.000 description 131
- 238000003786 synthesis reaction Methods 0.000 description 131
- 239000007787 solid Substances 0.000 description 123
- 238000006243 chemical reaction Methods 0.000 description 114
- 239000000543 intermediate Substances 0.000 description 114
- 238000005160 1H NMR spectroscopy Methods 0.000 description 91
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 86
- 239000000243 solution Substances 0.000 description 74
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 62
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 239000000203 mixture Substances 0.000 description 31
- 239000012071 phase Substances 0.000 description 31
- 238000001308 synthesis method Methods 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000000706 filtrate Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 28
- 239000002904 solvent Substances 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 25
- CXNIUSPIQKWYAI-UHFFFAOYSA-N 4,5-bis(diphenylphosphino)-9,9-dimethyl-xanthene Substances C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 23
- 238000000926 separation method Methods 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- 239000012065 filter cake Substances 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 19
- 238000001914 filtration Methods 0.000 description 19
- 238000010828 elution Methods 0.000 description 18
- 238000002953 preparative HPLC Methods 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 description 15
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 description 15
- 239000004698 Polyethylene Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 229910000024 caesium carbonate Inorganic materials 0.000 description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 12
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 9
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- LXRZFCICPHDASY-UHFFFAOYSA-N 7-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)spiro[1,3-dihydropyrido[2,3-d]pyrimidine-2,1'-cyclobutane]-4-one hydrochloride Chemical compound C1CC2(C1)NC3=C(C=CC(=N3)NC4=NC=NC5=C4C=CN5)C(=O)N2.Cl LXRZFCICPHDASY-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- AYVGBNGTBQLJBG-UHFFFAOYSA-N [3-(hydroxymethyl)cyclopentyl]methanol Chemical compound OCC1CCC(CO)C1 AYVGBNGTBQLJBG-UHFFFAOYSA-N 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ZDGRCTCNUFMITE-UHFFFAOYSA-N 4h-pyrimidin-5-one;hydrochloride Chemical compound Cl.O=C1CN=CN=C1 ZDGRCTCNUFMITE-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 4
- HYHMNJSJGMTZHG-UHFFFAOYSA-N CC1=C(N(C(=O)C(=C1)Br)N)C(=O)N Chemical compound CC1=C(N(C(=O)C(=C1)Br)N)C(=O)N HYHMNJSJGMTZHG-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical group [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- RZXHKUYBBAQDGZ-UHFFFAOYSA-N 2-amino-6-chloropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(Cl)N=C1N RZXHKUYBBAQDGZ-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- DBTKCXWYSQFAOA-UHFFFAOYSA-N 5-chloro-7-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)spiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclohexane]-4,8-dione hydrochloride Chemical compound C1CCC2(CC1)NC(=O)C3=C(C=C(C(=O)N3N2)NC4=NC=NC5=C4C=CN5)Cl.Cl DBTKCXWYSQFAOA-UHFFFAOYSA-N 0.000 description 3
- CMDIDTNMHQUVPE-UHFFFAOYSA-N 6-chlorohexan-2-one Chemical compound CC(=O)CCCCCl CMDIDTNMHQUVPE-UHFFFAOYSA-N 0.000 description 3
- UVZDHLMXNHGJNF-UHFFFAOYSA-N 7-[(4-amino-1,3,5-triazin-2-yl)amino]-5-chlorospiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound C1CC2(C1)NC(=O)C3=C(C=C(C(=O)N3N2)NC4=NC=NC(=N4)N)Cl.Cl UVZDHLMXNHGJNF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- LRVNEVWIPXMXDT-UHFFFAOYSA-N C1=C(C(=O)N(C(=C1Cl)C(=O)N)N)Br Chemical compound C1=C(C(=O)N(C(=C1Cl)C(=O)N)N)Br LRVNEVWIPXMXDT-UHFFFAOYSA-N 0.000 description 3
- JJLVWCFPPWSRDX-UHFFFAOYSA-N CC1=CC(=C(C(=C1C(=O)N)N)OC)Br Chemical compound CC1=CC(=C(C(=C1C(=O)N)N)OC)Br JJLVWCFPPWSRDX-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000006887 Ullmann reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 238000004537 pulping Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- SNAKUPLQASYKTC-AWEZNQCLSA-N (3S)-3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC[C@@H]1CN(CCC1)C(=O)NC1=CC=CC=C1 SNAKUPLQASYKTC-AWEZNQCLSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- RAVIQFQJZMTUBX-AWEZNQCLSA-N 1-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-2-(3,4-dichlorophenyl)ethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(CC1=CC(=C(C=C1)Cl)Cl)=O RAVIQFQJZMTUBX-AWEZNQCLSA-N 0.000 description 2
- BVKRPQCDGACLPX-UHFFFAOYSA-N 2-[4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyindol-1-yl]-N-methyl-N-phenylacetamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1=C2C=CN(C2=CC=C1)CC(=O)N(C1=CC=CC=C1)C BVKRPQCDGACLPX-UHFFFAOYSA-N 0.000 description 2
- XSGSVJZNHMUCEF-UHFFFAOYSA-N 2-amino-4-bromo-6-chlorobenzamide Chemical compound NC(=O)C1=C(N)C=C(Br)C=C1Cl XSGSVJZNHMUCEF-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- QKBARYIIIXIZGP-UHFFFAOYSA-N 3,3-dimethylcyclobutan-1-one Chemical compound CC1(C)CC(=O)C1 QKBARYIIIXIZGP-UHFFFAOYSA-N 0.000 description 2
- MCGROFKAAXXTBN-VIZOYTHASA-N 3,5-dihydroxy-N-[(E)-(4-hydroxy-3-nitrophenyl)methylideneamino]benzamide Chemical compound C1=CC(=C(C=C1/C=N/NC(=O)C2=CC(=CC(=C2)O)O)[N+](=O)[O-])O MCGROFKAAXXTBN-VIZOYTHASA-N 0.000 description 2
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 2
- ISXSUKUXUPLGTD-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(5-oxopyrrolidin-2-yl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2NC(CC2)=O)C=CC=1 ISXSUKUXUPLGTD-UHFFFAOYSA-N 0.000 description 2
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- QEIVWSRXBYOTAZ-UHFFFAOYSA-N 4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1CCN(CC1)C(=O)NC1=CC=CC=C1 QEIVWSRXBYOTAZ-UHFFFAOYSA-N 0.000 description 2
- GSOCTKHBFREQCV-UHFFFAOYSA-N 5-bromo-3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC(Br)=CN=C1C(O)=O GSOCTKHBFREQCV-UHFFFAOYSA-N 0.000 description 2
- RDDBEIMHNXNPLN-UHFFFAOYSA-N 5-chloro-1-methyl-7-(thieno[2,3-d]pyrimidin-4-ylamino)spiro[3H-pyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound CN1C2(CCC2)NC(=O)C3=C(C=C(C(=O)N31)NC4=C5C=CSC5=NC=N4)Cl.Cl RDDBEIMHNXNPLN-UHFFFAOYSA-N 0.000 description 2
- XVRIEWDDMODMGA-UHFFFAOYSA-N 5-chloropentan-2-one Chemical compound CC(=O)CCCCl XVRIEWDDMODMGA-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VHFYEFSVUFGACM-UHFFFAOYSA-N CCOC(=O)C1=C(C=C(C(=O)N1N)Br)C Chemical compound CCOC(=O)C1=C(C=C(C(=O)N1N)Br)C VHFYEFSVUFGACM-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003080 antimitotic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical class I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 1
- ZWHOTPNCEFWATE-CQSZACIVSA-N (3R)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-CQSZACIVSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- SVFDVVWBABHQFV-UHFFFAOYSA-N 2,3-dihydroimidazo[1,5-a]pyridine-1,5-dione Chemical class C1(NCN2C1=CC=CC2=O)=O SVFDVVWBABHQFV-UHFFFAOYSA-N 0.000 description 1
- FUHRWOFCZTZGQA-UHFFFAOYSA-N 2,6-dichloro-4-methylpyridine-3-carboxamide Chemical compound CC1=CC(Cl)=NC(Cl)=C1C(N)=O FUHRWOFCZTZGQA-UHFFFAOYSA-N 0.000 description 1
- RNIUHIHTGPHJEN-AWEZNQCLSA-N 2-[(3S)-1-[2-(3,4-dichlorophenyl)acetyl]piperidin-3-yl]oxy-6-(trifluoromethyl)pyridine-4-carbonitrile Chemical compound ClC=1C=C(C=CC=1Cl)CC(=O)N1C[C@H](CCC1)OC=1C=C(C#N)C=C(N=1)C(F)(F)F RNIUHIHTGPHJEN-AWEZNQCLSA-N 0.000 description 1
- DCGQVDFBDSTUML-AWEZNQCLSA-N 2-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidine-1-carbonyl]chromen-4-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1OC2=CC=CC=C2C(C=1)=O DCGQVDFBDSTUML-AWEZNQCLSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UXUSPQIPSTUNLJ-UHFFFAOYSA-N 2-amino-4-bromo-3-methoxy-6-methylbenzoic acid Chemical compound COC1=C(N)C(C(O)=O)=C(C)C=C1Br UXUSPQIPSTUNLJ-UHFFFAOYSA-N 0.000 description 1
- NEXCKCBRNWLQCX-UHFFFAOYSA-N 2-amino-4-bromo-6-chloro-3-fluorobenzoic acid Chemical compound C1=C(C(=C(C(=C1Br)F)N)C(=O)O)Cl NEXCKCBRNWLQCX-UHFFFAOYSA-N 0.000 description 1
- VOAQQGASEYDIKM-UHFFFAOYSA-N 2-amino-4-bromo-6-chlorobenzoic acid Chemical compound NC1=CC(Br)=CC(Cl)=C1C(O)=O VOAQQGASEYDIKM-UHFFFAOYSA-N 0.000 description 1
- SKBHNYYUVLRQNN-UHFFFAOYSA-N 2-amino-4-bromo-6-methylbenzaldehyde Chemical compound Cc1cc(Br)cc(N)c1C=O SKBHNYYUVLRQNN-UHFFFAOYSA-N 0.000 description 1
- FFCBTRXFKXWSQQ-UHFFFAOYSA-N 2-amino-4-bromo-6-methylbenzoic acid Chemical compound CC1=CC(Br)=CC(N)=C1C(O)=O FFCBTRXFKXWSQQ-UHFFFAOYSA-N 0.000 description 1
- YPFSAWFQVROHGL-UHFFFAOYSA-N 2-amino-6-chloro-4-methylpyridine-3-carboxamide Chemical compound CC1=CC(Cl)=NC(N)=C1C(N)=O YPFSAWFQVROHGL-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- BXFONYCBYSYAJE-UHFFFAOYSA-N 3,5-dibromopyridine-2-carboxylic acid Chemical class OC(=O)C1=NC=C(Br)C=C1Br BXFONYCBYSYAJE-UHFFFAOYSA-N 0.000 description 1
- MROVZCRMXJZHCN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxyethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCO)C=CC=1 MROVZCRMXJZHCN-UHFFFAOYSA-N 0.000 description 1
- LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- SONNQRNOTIAJDS-GFCCVEGCSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(2R)-2,3-dihydroxypropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC[C@H](CO)O)C=CC=1 SONNQRNOTIAJDS-GFCCVEGCSA-N 0.000 description 1
- FJPUKTJEFOXMJX-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[1-(hydroxymethyl)cyclopropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2(CC2)CO)C=CC=1 FJPUKTJEFOXMJX-UHFFFAOYSA-N 0.000 description 1
- ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 description 1
- FVQKGQNSCKJPIJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN2C(OCC2)=O)C=CC=1 FVQKGQNSCKJPIJ-UHFFFAOYSA-N 0.000 description 1
- ZUNFPBNHELLPPP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(dimethylamino)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN(C)C)C=CC=1 ZUNFPBNHELLPPP-UHFFFAOYSA-N 0.000 description 1
- AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- CSHMFIIPOVGVDN-UHFFFAOYSA-N 3-bromo-5-chloro-2-fluoroaniline Chemical compound NC1=CC(Cl)=CC(Br)=C1F CSHMFIIPOVGVDN-UHFFFAOYSA-N 0.000 description 1
- CAYJPMAXJIWLBZ-UHFFFAOYSA-N 3-bromo-5-chloro-2-methoxyaniline Chemical compound COC1=C(N)C=C(Cl)C=C1Br CAYJPMAXJIWLBZ-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- HOWFLZVASJDZRZ-UHFFFAOYSA-N 4-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OCC1CCN(CC1)C(=O)NC1=CC=CC=C1 HOWFLZVASJDZRZ-UHFFFAOYSA-N 0.000 description 1
- BHVKGDUOOHBRMZ-UHFFFAOYSA-N 4-bromo-2-chloro-6-nitrobenzoic acid Chemical compound OC(=O)c1c(Cl)cc(Br)cc1[N+]([O-])=O BHVKGDUOOHBRMZ-UHFFFAOYSA-N 0.000 description 1
- MOERBJIWBODDFC-UHFFFAOYSA-N 4-bromo-2-methyl-6-nitrobenzaldehyde Chemical compound BrC1=CC(=C(C=O)C(=C1)[N+](=O)[O-])C MOERBJIWBODDFC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- HPXSPJGSFHLODM-UHFFFAOYSA-N 5-bromo-1,2-dimethyl-3-nitrobenzene Chemical compound CC1=CC(Br)=CC([N+]([O-])=O)=C1C HPXSPJGSFHLODM-UHFFFAOYSA-N 0.000 description 1
- KQMXGSGRIHBQGJ-UHFFFAOYSA-N 5-bromo-1-chloro-2-methyl-3-nitrobenzene Chemical compound CC1=C(Cl)C=C(Br)C=C1[N+]([O-])=O KQMXGSGRIHBQGJ-UHFFFAOYSA-N 0.000 description 1
- OOKFCQHMHNKVKJ-UHFFFAOYSA-N 5-bromo-2-methyl-3-nitroaniline Chemical compound CC1=C(N)C=C(Br)C=C1[N+]([O-])=O OOKFCQHMHNKVKJ-UHFFFAOYSA-N 0.000 description 1
- ORYRABJCUIDNQA-UHFFFAOYSA-N 5-bromo-3-methyl-1-(3-nitroanilino)-6-oxopyridine-2-carboxamide Chemical compound CC1=C(N(C(=O)C(=C1)Br)NC2=CC(=CC=C2)[N+](=O)[O-])C(=O)N ORYRABJCUIDNQA-UHFFFAOYSA-N 0.000 description 1
- QUUUGYHRJCWXSN-UHFFFAOYSA-N 5-bromo-3-methyl-1-(3-nitroanilino)-6-oxopyridine-2-carboxylic acid Chemical compound CC1=C(N(C(=O)C(=C1)Br)NC2=CC(=CC=C2)[N+](=O)[O-])C(=O)O QUUUGYHRJCWXSN-UHFFFAOYSA-N 0.000 description 1
- ICINQANODCBKPF-UHFFFAOYSA-N 5-chloro-1,3',3'-trimethyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)spiro[3H-pyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound CC1(CC2(C1)NC(=O)C3=C(C=C(C(=O)N3N2C)NC4=NC=NC5=C4C=CN5)Cl)C.Cl ICINQANODCBKPF-UHFFFAOYSA-N 0.000 description 1
- NPNIIKDSOGUUHT-UHFFFAOYSA-N 5-chloro-7-(7H-purin-6-ylamino)spiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound C1CC2(C1)NC(=O)C3=C(C=C(C(=O)N3N2)NC4=NC=NC5=C4NC=N5)Cl.Cl NPNIIKDSOGUUHT-UHFFFAOYSA-N 0.000 description 1
- UVPYOKLGQCZIEJ-UHFFFAOYSA-N 5-chloro-7-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)spiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound C1CC2(C1)NC(=O)C3=C(C=C(C(=O)N3N2)NC4=NC=NC5=C4C=CN5)Cl.Cl UVPYOKLGQCZIEJ-UHFFFAOYSA-N 0.000 description 1
- COVMCVSAXJNIOT-UHFFFAOYSA-N 5-chloro-7-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)spiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclopentane]-4,8-dione hydrochloride Chemical compound C1CCC2(C1)NC(=O)C3=C(C=C(C(=O)N3N2)NC4=NC=NC5=C4C=CN5)Cl.Cl COVMCVSAXJNIOT-UHFFFAOYSA-N 0.000 description 1
- HCODKMRNLGSBDQ-UHFFFAOYSA-N 5-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)spiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound CC1=C2C(=O)NC3(CCC3)NN2C(=O)C(=C1)NC4=NC=NC5=C4C=CN5.Cl HCODKMRNLGSBDQ-UHFFFAOYSA-N 0.000 description 1
- JRVXDHZNSOUCBT-UHFFFAOYSA-N 5-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)spiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclohexane]-4,8-dione hydrochloride Chemical compound CC1=C2C(=O)NC3(CCCCC3)NN2C(=O)C(=C1)NC4=NC=NC5=C4C=CN5.Cl JRVXDHZNSOUCBT-UHFFFAOYSA-N 0.000 description 1
- MMRCWWRFYLZGAE-ZBZRSYSASA-N 533u947v6q Chemical compound O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O MMRCWWRFYLZGAE-ZBZRSYSASA-N 0.000 description 1
- DLPWLDMYEGMCRB-UHFFFAOYSA-N 6-[4-[3-(dimethylamino)propyl]piperazin-1-yl]pyrimidin-4-amine Chemical compound CN(CCCN1CCN(CC1)C1=CC(=NC=N1)N)C DLPWLDMYEGMCRB-UHFFFAOYSA-N 0.000 description 1
- RHWUZJRHLMNJJF-UHFFFAOYSA-N 7-[(6-amino-5-methoxypyrimidin-4-yl)amino]-5-chlorospiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound COC1=C(N=CN=C1NC2=CC(=C3C(=O)NC4(CCC4)NN3C2=O)Cl)N.Cl RHWUZJRHLMNJJF-UHFFFAOYSA-N 0.000 description 1
- VQDDIDISQLSXTR-UHFFFAOYSA-N 7-[(6-aminopyrimidin-4-yl)amino]-5-chloro-1-methylspiro[3H-pyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound CN1C2(CCC2)NC(=O)C3=C(C=C(C(=O)N31)NC4=NC=NC(=C4)N)Cl.Cl VQDDIDISQLSXTR-UHFFFAOYSA-N 0.000 description 1
- IGJHMLHRNQDSSV-UHFFFAOYSA-N 7-[(6-aminopyrimidin-4-yl)amino]-5-methylspiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclohexane]-4,8-dione hydrochloride Chemical compound CC1=C2C(=O)NC3(CCCCC3)NN2C(=O)C(=C1)NC4=NC=NC(=C4)N.Cl IGJHMLHRNQDSSV-UHFFFAOYSA-N 0.000 description 1
- KPVLRRNZEKKHPU-UHFFFAOYSA-N 7-[[6-amino-5-(1-methylpyrazol-4-yl)pyrimidin-4-yl]amino]-5-chlorospiro[1,3-dihydropyrido[2,1-f][1,2,4]triazine-2,1'-cyclobutane]-4,8-dione hydrochloride Chemical compound CN1C=C(C=N1)C2=C(N=CN=C2NC3=CC(=C4C(=O)NC5(CCC5)NN4C3=O)Cl)N.Cl KPVLRRNZEKKHPU-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- NRLQBVLOUUPAMI-UHFFFAOYSA-N 8-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2CCC3(CNC(O3)=O)CC2)C=CC=1 NRLQBVLOUUPAMI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 description 1
- 229940127512 Androgen Synthesis Inhibitors Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 102100021677 Baculoviral IAP repeat-containing protein 2 Human genes 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UXKCLTPQRBKROC-UHFFFAOYSA-N C(C)(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)C1=CC=CC=C1.[P] Chemical group C(C)(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)C1=CC=CC=C1.[P] UXKCLTPQRBKROC-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- SEOLWBNDLDBFDI-UHFFFAOYSA-N CC1(NC(=O)C2=C(C=C(C(=O)N2N1)Br)Cl)CCCCl Chemical compound CC1(NC(=O)C2=C(C=C(C(=O)N2N1)Br)Cl)CCCCl SEOLWBNDLDBFDI-UHFFFAOYSA-N 0.000 description 1
- ZOGRUJDKCDGUMD-UHFFFAOYSA-N CC1=C(N(C(=O)C(=C1)Br)NC(C)C)C(=O)N Chemical compound CC1=C(N(C(=O)C(=C1)Br)NC(C)C)C(=O)N ZOGRUJDKCDGUMD-UHFFFAOYSA-N 0.000 description 1
- JJOUOKHXENRFPX-UHFFFAOYSA-N CC1=C(N(C(=O)C(=C1)Br)NC(C)C)C(=O)O Chemical compound CC1=C(N(C(=O)C(=C1)Br)NC(C)C)C(=O)O JJOUOKHXENRFPX-UHFFFAOYSA-N 0.000 description 1
- IJIPQIZGYIFNJV-UHFFFAOYSA-N CC1=C2C(=O)NC3(CCC(=O)N3N2C(=O)C(=C1)NC4=NC=NC5=C4C=CN5)C Chemical compound CC1=C2C(=O)NC3(CCC(=O)N3N2C(=O)C(=C1)NC4=NC=NC5=C4C=CN5)C IJIPQIZGYIFNJV-UHFFFAOYSA-N 0.000 description 1
- YKUWXLQHMXQHLY-UHFFFAOYSA-N CC1=C2C(=O)NC3(CCC3)N(N2C(=O)C(=C1)NC4=NC=NC5=C4C=CN5)C6=CC=CC(=C6)NC(=O)C=C Chemical compound CC1=C2C(=O)NC3(CCC3)N(N2C(=O)C(=C1)NC4=NC=NC5=C4C=CN5)C6=CC=CC(=C6)NC(=O)C=C YKUWXLQHMXQHLY-UHFFFAOYSA-N 0.000 description 1
- XCJLLHUCWXHOBR-UHFFFAOYSA-N CC1=CC(=C(C2=C1C(=O)NC3(N2)CCCC3)OC)Br Chemical compound CC1=CC(=C(C2=C1C(=O)NC3(N2)CCCC3)OC)Br XCJLLHUCWXHOBR-UHFFFAOYSA-N 0.000 description 1
- YMOYJPWDGKAPTD-UHFFFAOYSA-N CC1=NN2C(=C(C=C(C2=O)Br)Cl)C(=O)N1 Chemical compound CC1=NN2C(=C(C=C(C2=O)Br)Cl)C(=O)N1 YMOYJPWDGKAPTD-UHFFFAOYSA-N 0.000 description 1
- GMUCZJFWHRSUQA-UHFFFAOYSA-N CCOC(=O)C1=C(C=C(C(=O)N1NC(C)C)Br)C Chemical compound CCOC(=O)C1=C(C=C(C(=O)N1NC(C)C)Br)C GMUCZJFWHRSUQA-UHFFFAOYSA-N 0.000 description 1
- 229940127272 CD73 inhibitor Drugs 0.000 description 1
- CGVFGUTYCXCFEH-UHFFFAOYSA-N CN1C2(CCC2)NC(=O)C3=C(C=C(C(=O)N31)NC4=CC(=NC=N4)N5CCN(CC5)CCCN(C)C)Cl Chemical compound CN1C2(CCC2)NC(=O)C3=C(C=C(C(=O)N31)NC4=CC(=NC=N4)N5CCN(CC5)CCCN(C)C)Cl CGVFGUTYCXCFEH-UHFFFAOYSA-N 0.000 description 1
- OYZOQEGRLYSGBP-UHFFFAOYSA-N COC1=C(C=C(C(=C1N)C(=O)O)Cl)Br Chemical compound COC1=C(C=C(C(=C1N)C(=O)O)Cl)Br OYZOQEGRLYSGBP-UHFFFAOYSA-N 0.000 description 1
- AXTSKPKDYTVJGP-UHFFFAOYSA-N COC1=C(C=C(C2=C1NC(=O)C2=O)Cl)Br Chemical compound COC1=C(C=C(C2=C1NC(=O)C2=O)Cl)Br AXTSKPKDYTVJGP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical group [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010058545 Cyclin D3 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000008095 Malignant Carcinoid Syndrome Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UAGJVSRUFNSIHR-UHFFFAOYSA-N Methyl levulinate Chemical compound COC(=O)CCC(C)=O UAGJVSRUFNSIHR-UHFFFAOYSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940124614 TLR 8 agonist Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- JDCLUYDBENDDSR-NSHDSACASA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-(5-methyl-1,3,4-oxadiazol-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1OC(=NN=1)C JDCLUYDBENDDSR-NSHDSACASA-N 0.000 description 1
- RWQJLIWMOBYOTI-AWEZNQCLSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyridin-3-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=CC=1 RWQJLIWMOBYOTI-AWEZNQCLSA-N 0.000 description 1
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 1
- CDGFEINVQHEUQV-UHFFFAOYSA-N [1,3]thiazolo[5,4-d]pyrimidine Chemical compound N1=CN=C2SC=NC2=C1 CDGFEINVQHEUQV-UHFFFAOYSA-N 0.000 description 1
- GXFIJNNOECYQOJ-UHFFFAOYSA-N [2-[1-(1-methylpyrazol-4-yl)indol-4-yl]oxy-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound CN1N=CC(=C1)N1C=CC2=C(C=CC=C12)OC1=NC(=CC(=C1)CN)C(F)(F)F GXFIJNNOECYQOJ-UHFFFAOYSA-N 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 description 1
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 1
- JOSCNYCOYXTLTN-GFCCVEGCSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-(hydroxymethyl)pyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)CO JOSCNYCOYXTLTN-GFCCVEGCSA-N 0.000 description 1
- BYWBCSRCPLBDFU-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)N BYWBCSRCPLBDFU-CYBMUJFWSA-N 0.000 description 1
- LJHFUFVRZNYVMK-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)O LJHFUFVRZNYVMK-CYBMUJFWSA-N 0.000 description 1
- JWSIZPAOIFLWKM-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]methanone Chemical compound CN(C)C1CN(CC1O)C(=O)c1cccc(Oc2cc(CN)cc(n2)C(F)(F)F)c1 JWSIZPAOIFLWKM-UHFFFAOYSA-N 0.000 description 1
- KDSYNTPPPISIJB-UHFFFAOYSA-N [3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]phenyl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCc1cc(OCc2cccc(c2)C(=O)N2CC(O)C(F)C2)nc(c1)C(F)(F)F KDSYNTPPPISIJB-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229960002692 allylestrenol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229960003982 apatinib Drugs 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 208000021592 benign granular cell tumor Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- DAMJCWMGELCIMI-UHFFFAOYSA-N benzyl n-(2-oxopyrrolidin-3-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNC1=O DAMJCWMGELCIMI-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 208000005761 carcinoid heart disease Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- SIIJRCRHAIMFNT-UHFFFAOYSA-N cyclopropanamine;hydrochloride Chemical compound Cl.NC1CC1 SIIJRCRHAIMFNT-UHFFFAOYSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 1
- 229960003309 dienogest Drugs 0.000 description 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000004586 dihydrobenzopyranyl group Chemical group O1C(CCC2=C1C=CC=C2)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- HYBPMJROEPLLMI-UHFFFAOYSA-N ethyl 5-bromo-3-methyl-1-(3-nitroanilino)-6-oxopyridine-2-carboxylate Chemical compound CCOC(=O)C1=C(C=C(C(=O)N1NC2=CC(=CC=C2)[N+](=O)[O-])Br)C HYBPMJROEPLLMI-UHFFFAOYSA-N 0.000 description 1
- PTRZFSDOOXZABV-UHFFFAOYSA-N ethyl 5-bromo-3-methyl-1-oxidopyridin-1-ium-2-carboxylate Chemical compound BrC=1C=C(C(=[N+](C=1)[O-])C(=O)OCC)C PTRZFSDOOXZABV-UHFFFAOYSA-N 0.000 description 1
- GJLHANFPVBOAPL-UHFFFAOYSA-N ethyl 5-bromo-3-methyl-6-oxo-1-(propan-2-ylideneamino)pyridine-2-carboxylate Chemical compound CCOC(=O)C1=C(C=C(C(=O)N1N=C(C)C)Br)C GJLHANFPVBOAPL-UHFFFAOYSA-N 0.000 description 1
- YQXGIJOPAJQRQC-UHFFFAOYSA-N ethyl 5-bromo-3-methyl-6-oxo-1H-pyridine-2-carboxylate Chemical compound BrC1=CC(=C(NC1=O)C(=O)OCC)C YQXGIJOPAJQRQC-UHFFFAOYSA-N 0.000 description 1
- ZZKIZHFVMLOYHR-UHFFFAOYSA-N ethyl 5-bromo-3-methylpyridine-2-carboxylate Chemical compound CCOC(=O)C1=NC=C(Br)C=C1C ZZKIZHFVMLOYHR-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960004761 gestrinone Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000005233 imidazopyridazines Chemical class 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940095009 interferon gamma-1a Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229950005692 larotaxel Drugs 0.000 description 1
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960004655 masitinib Drugs 0.000 description 1
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000667 mepartricin Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- ALPPGSBMHVCELA-WHUUVLPESA-N methyl (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-7-oxoheptan-2-yl]-1,3,5,7,9,13,37-heptahydroxy-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate methyl (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,7,9,13,37-heptahydroxy-17-[5-hydroxy-7-[4-(methylamino)phenyl]-7-oxoheptan-2-yl]-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate Chemical compound CC1\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C(O[C@H]2[C@H]([C@@H](N)[C@H](O)[C@@H](C)O2)O)CC(O2)C(C(=O)OC)C(O)CC2(O)CC(O)CC(O)CC(O)CC(O)CC(=O)CC(O)CC(=O)OC1C(C)CCC(O)CC(=O)C1=CC=C(N)C=C1.C1=CC(NC)=CC=C1C(=O)CC(O)CCC(C)C1C(C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(O[C@H]2[C@H]([C@@H](N)[C@H](O)[C@@H](C)O2)O)CC(O2)C(C(=O)OC)C(O)CC2(O)CC(O)CC(O)CC(O)CC(O)CC(=O)CC(O)CC(=O)O1 ALPPGSBMHVCELA-WHUUVLPESA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000004130 myoblastoma Diseases 0.000 description 1
- YJRGRZJKGMBHIB-UHFFFAOYSA-N n,n-dimethyl-3-piperazin-1-ylpropan-1-amine Chemical compound CN(C)CCCN1CCNCC1 YJRGRZJKGMBHIB-UHFFFAOYSA-N 0.000 description 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960004911 nomegestrol Drugs 0.000 description 1
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SJECIYLGISUNRO-UHFFFAOYSA-N o-diphenylphosphorylhydroxylamine Chemical compound C=1C=CC=CC=1P(=O)(ON)C1=CC=CC=C1 SJECIYLGISUNRO-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 229950001094 ortataxel Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical group [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 108700027936 paclitaxel poliglumex Proteins 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical class [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- BYTCDABWEGFPLT-UHFFFAOYSA-L potassium;sodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[K+] BYTCDABWEGFPLT-UHFFFAOYSA-L 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- KEEYRQROLDCTFF-UHFFFAOYSA-N tert-butyl N-(6-amino-5-chloropyrimidin-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=NC=NC(=C1Cl)N KEEYRQROLDCTFF-UHFFFAOYSA-N 0.000 description 1
- PCLZMDKMCJIBME-UHFFFAOYSA-N tert-butyl N-(6-amino-5-fluoropyrimidin-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=NC=NC(=C1F)N PCLZMDKMCJIBME-UHFFFAOYSA-N 0.000 description 1
- PKHIIDRUXBVFCZ-UHFFFAOYSA-N tert-butyl n-(6-aminopyrimidin-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(N)=NC=N1 PKHIIDRUXBVFCZ-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229950009016 tesetaxel Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000008634 thiazolopyrimidines Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- GINSRDSEEGBTJO-UHFFFAOYSA-N thietane 1-oxide Chemical compound O=S1CCC1 GINSRDSEEGBTJO-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229950005839 vinzolidine Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
本发明公开了一种如式I或I’所示结构的新型MNK抑制剂。本发明的MNK抑制剂在体内和体外均具有良好的抑制MNK1和/或MNK2水平的作用,进一步本发明的MNK抑制剂还可以有效治疗MNK1和/或MNK2介导的疾病,例如:癌症。
Description
技术领域
本发明涉及一种新型MNK抑制剂、其药物组合物及其作为癌症治疗剂的用途。
背景技术
MAP相互作用性激酶1和2(MNK1和MNK2)是一类丝氨酸/苏氨酸蛋白激酶,可以被ERK或p38激活并且能够使真核起始因子4E(eIF4E)磷酸化,在蛋白质的合成和细胞功能稳定中至关重要。eIF4E涉及到帽(cap)-依赖性翻译启动。eIF4E蛋白于mRNA的5'帽结构相互结合,对于帽依赖性翻译启动是必需的。多项证据表明eIF4E在体内表现出真正的致癌促进作用。eIF4E在多种类型的人类癌症中过度表达,并且与肿瘤患者的预后不良有关(MamaneY,et al.Oncogene,2004 23:3172-79;Graff JR,et al.,Cancer Res,2009 69:3866-73;Ruggero D,et al.Nat Med,2004 10:484-6),包括结肠癌、乳腺癌(Chrestensen,C.A.,etal.,J.Biol.Chem.,2007 282(7):4243-52)、膀胱癌、肺癌、前列腺癌(Tomlins,S.A.,etal.,Nat.Genet.,2007 39(1):41-51)、胃肠道癌、头颈癌、霍奇金氏淋巴瘤、成神经细胞瘤、胶质瘤(Bredel,M.,et al,Cancer Res.,2005 65(10):4088-96)、卵巢癌(Hendrix,N.D.,et al.,Cancer Res.,2006 66(3):1354-62)、胰腺癌(Lapointe,J.,et al.,Proc.Natl.Acad.Sci.USA,2004,101(3):811-16)等。同样的,过表达eIF4E的转基因小鼠在多个器官中的肿瘤发生率大大提高。临床结果显示,不仅仅eIF4E的过表达有助于肿瘤的进展,即使是eIF4E的过磷酸化也可以有助于肿瘤的进展。已经在多种实体瘤和淋巴瘤中观察到eIF4E磷酸化的增强与患者的预后不良相关,特别是在非小细胞肺癌中。MNK1在血液系统恶性肿瘤中高表达(Worch J.,et al.,Oncogene,2004 23:9162-72),MNK1和MNK2在实体肿瘤如胶质瘤和卵巢癌中表达均上调。
MNK/eIF4E轴参与促血管生成,抗细胞凋亡的表达,细胞周期和运动蛋白,Ser209位点上eIF4E的磷酸化促进其致癌潜力(Topisirovic,I.,et al.,Cancer Res.,2004 64(23):8639-42),而MNK1/2是已知驱动该过程的唯一激酶。MNK1/2对eIF4E的磷酸化可以促进多种促癌基因蛋白的表达,包括MCL-1(Wendel,H.G.,et al.,Genes Dev.,2007 21(24):3232-37),FGF2,c-Myc,VEGF,MMP3,CCL2,BIRC2,cyclin D1(De Benedetti,A.,et al.,Cell Biol.,1999,31(1):59-72),细胞周期蛋白D3(Graff,J.R.,et al.,Cancer Res.,2008 68(3):631-34)和ODC。并且在Ras和c-Myc诱导的转化过程中是必需的。在多条细胞内信号传导途径中起到关键作用。包括雷帕霉素复合物1(mTORC1)和ERK(经典MAP激酶)途径。这两条信号传导途径都经常在癌症中被激活。
目前,有多份关于MNK1和/或MNK2抑制剂的专利公开,例如:WO2015/200481,WO2017/075394,WO2017/075412,WO2017/087808公开了一系列异吲哚-1-酮和2,3-二氢咪唑并[1,5-a]吡啶-1,5-二酮类化合物;WO2017/085484,WO2017/085483,WO2014/044691,WO2014/048894公开了一系列噻唑并嘧啶和吡咯并嘧啶类化合物;WO2015/050505,WO2013/147711公开了一系列咪唑并哒嗪类化合物。
尽管对MNKs研究在不断深入,也有小分子实体进入临床研究阶段,但是还没有真正的进入市场的MNK抑制剂,随着对MNK抑制剂构效关系的不断深入研究,本发明公开了一类新型的MNK抑制剂,具有良好的MNK1和MNK2抑制效果。
发明内容
本发明所要解决的技术问题在于,提供了一种新型如式I或I’所示化合物、其药物组合物及应用。本发明的如式I或I’所示化合物具有良好的MNK1和/或MNK2抑制作用,可以有效治疗和/或缓解由MNK1和/或MNK2介导的各种相关疾病,例如癌症。
本发明提供了一种如式I所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐;
其中,W1和W2分别独立地为=O、=S、=NH、=N-OH或=N-O(C1-6烷基);
R为-NH-Cy或Cy;
R1为H、-OH、-NH2、RA、-NH-RA、-NH-C(O)-RA或-O-RA;
R2为H、CN、氘代C1-4烷基或RB;
R3为H、C1-6烷基、C2-6烯基或C2-6炔基;所述R3为未取代,或者选择性被1~3个R9取代在任意位置;
R4为H、C1-6烷基、C2-6烯基、C2-6炔基、C6-10芳基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、C6-10芳基C1-6烷基、5-6元杂芳基C1-6烷基、C3-8环烷基C1-6烷基或3-8元杂环烷基C1-6烷基;所述R4为未取代,或者选择性被1~3个R9取代在任意位置;
所述R1、R2、R3和R4分别为独立取代基,或者
1)R1和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
2)R2和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
3)R3和R4与其共同连接的碳原子一起形成C3-10环烷基或3-10元杂环烷基;所述C3-10环烷基或3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;或
4)R2和R3相互连接与α键共同形成双键;
R5和R5a分别独立地为氢、卤素、氰基、C1-4烷基、卤代C1-4烷基、卤代C1-4烷氧基或C1-4烷氨基;
Cy为5-10元杂芳环;所述Cy为未取代,或者选择性被1~3个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC、-C(O)RC和-C(O)N(RC)2的取代基取代在任意位置;
每个RA独立地为C1-8烷基、C2-8烯基或C2-8炔基;所述RA为未取代,或者选择性被1~3个选自卤素、-OH、-NH2、氧代基、C1-3烷氧基和C1-3烷氨基的取代基取代在任意位置;
每个RB独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基或-(CH2)n-(3-8元杂环烷基);所述RB为未取代,或者选择性被1~3个R9取代在任意位置;
每个RC独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基、-(CH2)n-(3-8元杂环烷基)或-(3-8元杂环烷基)-C1-6烷基;所述RC为未取代,或者选择性被1~3个R10取代在任意位置;
每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、-C(O)Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基、卤代C1-4烷氧基、-(CH2)n-NH2、-(CH2)n-OH、-(CH2)n-(C1-4烷氨基)或-(CH2)n-(C1-4烷氧基);
每个Ra独立地为C1-6烷基或C2-6烯基;
n为1、2、3或4。
本发明提供了一种如式I’所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐;
其中,W2为=O、=S、=NH、=N-OH或=N-O(C1-6烷基);
A1为N或CR5;
A2为N或CR5a;
A3为N或CR5b;
R为-NH-Cy或Cy;
R1为H、-OH、-NH2、RA、-NH-RA、-NH-C(O)-RA或-O-RA;
R2为H、CN、氘代C1-4烷基或RB;
R3为H、C1-6烷基、C2-6烯基或C2-6炔基;所述R3为未取代,或者选择性被1~3个R9取代在任意位置;
R4为H、C1-6烷基、C2-6烯基、C2-6炔基、C6-10芳基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、C6-10芳基C1-6烷基、5-6元杂芳基C1-6烷基、C3-8环烷基C1-6烷基或3-8元杂环烷基C1-6烷基;所述R4为未取代,或者选择性被1~3个R9取代在任意位置;
所述R1、R2、R3和R4分别为独立取代基,或者
1)R1和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
2)R2和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
3)R3和R4与其共同连接的碳原子一起形成C3-10环烷基或3-10元杂环烷基;所述C3-10环烷基或3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;或
4)R2和R3相互连接与α键共同形成双键;
R5、R5a和R5b分别独立地为氢、卤素、氰基、C1-4烷基、卤代C1-4烷基、卤代C1-4烷氧基或C1-4烷氨基;
Cy为5-10元杂芳环;所述Cy为未取代,或者选择性被1~3个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC、-C(O)RC和-C(O)N(RC)2的取代基取代在任意位置;
每个RA独立地为C1-8烷基、C2-8烯基或C2-8炔基;所述RA为未取代,或者选择性被1~3个选自卤素、-OH、-NH2、氧代基、C1-3烷氧基和C1-3烷氨基的取代基取代在任意位置;
每个RB独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基或-(CH2)n-(3-8元杂环烷基);所述RB为未取代,或者选择性被1~3个R9取代在任意位置;
每个RC独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基、-(CH2)n-(3-8元杂环烷基)或-(3-8元杂环烷基)-C1-6烷基;所述RC为未取代,或者选择性被1~3个R10取代在任意位置;
每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、-C(O)Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基、卤代C1-4烷氧基、-(CH2)n-NH2、-(CH2)n-OH、-(CH2)n-(C1-4烷氨基)或-(CH2)n-(C1-4烷氧基);
每个Ra独立地为C1-6烷基或C2-6烯基;
n为1、2、3或4。
以下所述的如式I或I’所述的所有实施方案、及任意实施方案的组合均包含在本发明如式I或I’所示的结构式的范围中。
在一些实施方案中,所述的如式I所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐里某些基团的定义可如下所述,未描述的基团可如上任一方案所述:
其中,W1为O;W2为O;
R为-NH-Cy;
R1为H、-OH、-NH2、RA、-NH-RA、-NH-C(O)-RA或-O-RA;
R2和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
R4为H、C1-6烷基、C2-6烯基、C2-6炔基、C6-10芳基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、C6-10芳基C1-6烷基、5-6元杂芳基C1-6烷基、C3-8环烷基C1-6烷基或3-8元杂环烷基C1-6烷基;所述R4为未取代,或者选择性被1~3个R9取代在任意位置;
R5为氢、卤素、氰基或C1-4烷基;
R5a为氢;
Cy为5-10元杂芳环;所述Cy为未取代,或者选择性被1~3个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC、-C(O)RC和-C(O)N(RC)2的取代基取代在任意位置;
每个RA独立地为C1-8烷基、C2-8烯基或C2-8炔基;所述RA为未取代,或者选择性被1~3个选自卤素、-OH、-NH2、氧代基、C1-3烷氧基和C1-3烷氨基的取代基取代在任意位置;
每个RB独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基或-(CH2)n-(3-8元杂环烷基);所述RB为未取代,或者选择性被1~3个R9取代在任意位置;
每个RC独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基、-(CH2)n-(3-8元杂环烷基)或-(3-8元杂环烷基)-C1-6烷基;所述RC为未取代,或者选择性被1~3个R10取代在任意位置;
每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、-C(O)Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基;
每个Ra独立地为C1-6烷基或C2-6烯基;
n为1、2、3或4。
在一些实施方案中,每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、-C(O)Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,所述R9为H、-NH2、-OH、F、Cl、=O、-NHC(O)-C2-6烯基、-C(O)-C2-6烯基、-NHS(O)2-C2-6烯基、C1-4烷基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,所述R9为H、-NH2、-OH、F、Cl、=O、-NHC(O)-C2-6烯基、-NHS(O)2-C2-6烯基、C1-4烷基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,所述R9为H、F、Cl、=O、-NHC(O)-C2-6烯基或C1-4烷基。
在一些实施方案中,所述R10为H、-CN、-NH2、-OH、F、Cl、=O、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,所述R10为H、-NH2或C1-4烷氨基。
在一些实施方案中,所述R10为H。
在一些实施方案中,所述RA为C1-6烷基或C2-6烯基;所述RA为未取代,或者选择性被1~3个选自F、Cl、-OH、-NH2、=O、-OCH3和-N(CH3)2的取代基取代在任意位置。
在一些实施方案中,所述RB为C1-6烷基(例如:甲基、乙基、正丙基、异丙基)、C2-6烯基(例如:烯丙基)、C3-6环烷基(例如:环丙基或环丁基)、苯基或5-6元杂芳基;所述RB为未取代,或者选择性被1~3个R9取代在任意位置;R9的定义如前所述。
在一些实施方案中,所述RC独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基或-(CH2)n-(3-8元杂环烷基);所述RC为未取代,或者选择性被1~3个R10取代在任意位置;
在一些实施方案中,所述RC独立地为C1-6烷基、C2-6烯基、苯基、5-6元杂芳基、C3-6环烷基、3-6元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-6环烷基或-(CH2)n-(3-6元杂环烷基);所述RC为未取代,或者选择性被1~3个R10取代在任意位置;其中n优选为1、2或3;R10的定义如前所述。
在一些实施方案中,所述RC独立地为C1-6烷基或C3-6环烷基;所述RC为未取代,或者选择性被1~3个R10取代在任意位置;其中R10的定义如前所述。
在一些实施方案中,所述RC独立地为C1-6烷基(例如:甲基、乙基、正丙基、异丙基或叔丁基)或C3-6环烷基(例如:环丙基)。
在一些实施方案中,所述R1为H、-OH、-OCH3、-NH2、-NH(CH3)、-NH(CH2CH3)或-NH(CH2CH=CH2)。
在一些实施方案中,所述R1为H、-OH、-NH2、-NH(CH3)或-NH(CH2CH3)。
在一些实施方案中,所述R1为H。
在一些实施方案中,R2为H、CD3或RB,其中,RB的定义如前所述。
在一些实施方案中,R2为H或RB,其中,RB的定义如前所述。。
在一些实施方案中,所述R2为H、C1-6烷基、C2-6烯基、C3-6环烷基、苯基或5-6元杂芳基;所述R2为未取代,或者选择性被1~3、1~2个或1个选自F、Cl、=O、-NHC(O)-C2-6烯基和C1-4烷基的取代基取代在任意位置。
在一些实施方案中,所述R2为H、CD3、C1-6烷基、C2-6烯基、C3-6环烷基、苯基或5-6元杂芳基;所述R2为未取代,或者选择性被1~3、1~2个或1个选自F、Cl、=O、-NHC(O)-C2-6烯基和C1-4烷基的取代基取代在任意位置。
在一些实施方案中,所述R3为H或C1-6烷基;所述R3为未取代,或者选择性被1~3、1~2或1个R9取代在任意位置;所述R9的定义如前所述。
在一些实施方案中,所述R3为H或C1-6烷基。
在一些实施方案中,所述R3为H、甲基或乙基。
在一些实施方案中,所述R4为H、C1-6烷基、苯基、5-6元杂芳基、C3-6环烷基或3-6元杂环烷基;所述R4为未取代,或者选择性被1~3、1~2或1个R9取代在任意位置;所述R9的定义如前所述。
在一些实施方案中,所述R4为甲基、乙基、正丙基、异丙基、苯基、吡啶基、环丙基、环丁基、环戊基或环己基;所述R4为未取代,或者选择性被1~3、1~2或1个氟、氯和甲基的取代基取代在任意位置。
在一些实施方案中,所述R3和R4分别为独立取代基。
在一些实施方案中,所述R3和R4与其共同连接的碳原子一起形成C3-10环烷基或3-10元杂环烷基;所述C3-10环烷基或3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;所述R9的定义如前所述。
在一些实施方案中,所述R3和R4与其共同连接的碳原子一起形成C3-10环烷基更优选为环丙基、环丁基、环戊基、环己基、2,3-二氢-1H-茚基、2,3-二氢-1H-茚基-1-酮、螺[3,2]己基或螺[3.3]庚基。
在一些实施方案中,所述R3和R4与其共同连接的碳原子一起形成3-10元杂环烷基更优选为3-8元杂环烷基,例如:四氢呋喃基、吡咯烷基、氮杂环丁基、哌啶基或1-氧代-硫杂环丁基。
在一些实施方案中,所述R1和R3分别为独立取代基。
在一些实施方案中,所述R1和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置。
在一些实施方案中,所述R1和R3相互连接形成4-8元杂环烷基。
在一些实施方案中,所述R1和R3相互连接形成5-6元杂环烷基。
在一些实施方案中,所述R2和R3分别为独立取代基。
在一些实施方案中,所述R2和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置。
在一些实施方案中,所述R2和R3相互连接形成4-8元杂环烷基;所述4-8元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置。
在一些实施方案中,所述R2和R3相互连接形成5-6元杂环烷基;所述5-6元杂环烷基为未取代,或者选择性被1个=O取代在任意位置。
在一些实施方案中,所述R2和R3相互连接与α键(单键)共同形成双键。
在一些实施方案中,R5为氢、卤素、氰基、C1-4烷氧基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,R5为氢、卤素或C1-4烷基。
在一些实施方案中,所述R5为H、F、Cl或-CH3。
在一些实施方案中,R5a为氢、卤素、氰基、C1-4烷氧基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,R5a为氢。
在一些实施方案中,R5b为氢、卤素、氰基、C1-4烷氧基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,R5b为氢、卤素、C1-4烷氧基或C1-4烷基。
在一些实施方案中,R5b为H、F、Cl、-CH3或-OCH3。
在一些实施方案中,A1为CR5,A2为CH,A3为N或CR5b。
在一些实施方案中,所述R为 其中,R6、R7和R8分别独立地为H、卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC或-NHS(O)2RC;R6和R7分别为独立取代基,或者R6和R7相互连接形成杂芳基或杂环烷基;所述杂芳基或杂环烷基为未取代,或者选择性被1~3个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC、-C(O)RC和-C(O)N(RC)2的取代基取代在任意位置;RC的定义如前所述。
在一些实施方案中,所述R为其中,R6、R7和R8分别独立地为H、卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC或-NHS(O)2RC;R6和R7分别为独立取代基,或者R6和R7与其连接的原子一起形成杂芳基或杂环烷基;所述杂芳基或杂环烷基为未取代,或者选择性被1~3个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC、-C(O)RC和-C(O)N(RC)2的取代基取代在任意位置;RC的定义如前所述。
在一些实施方案中,所述R为 其中,R6、R7和R8分别独立地为H、卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC或-NHS(O)2RC;RC的定义如前所述。
在一些实施方案中,所述R8为H。
在一些实施方案中,所述R6为H、F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基或1-甲基-1H-吡唑基。
在一些实施方案中,所述R7为H、-NH2、-NHRC、-NH-ORC或-NHC(O)RC;RC的定义如前所述。
在一些实施方案中,所述R7为H、-NH2、-NHRC或-NHC(O)RC;RC的定义如前所述。
在一些实施方案中,所述R6和R7与其连接的原子一起形成5-6元杂芳基或5-6元杂环烷基;所述5-6元杂芳基或5-6元杂环烷基为未取代,或者选择性被1-2或1个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC和-NHC(O)RC的取代基取代在任意位置;所述RC的定义如前所述。
在一些实施方案中,所述R6和R7与其连接的原子一起形成5-6元杂芳基或杂环烷基;所述5-6元杂芳基或杂环烷基为未取代,或者选择性被1-2或1个选自F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基、-NHRC、-NH-ORC和-NHC(O)RC的取代基取代在任意位置;所述RC的定义如前所述。
在一些实施方案中,所述R为如下任一结构:
在一些实施方案中,所述R11为H、F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基、-NHRC、-NH-ORC或-NHC(O)RC;所述RC的定义如前所述。
在一些实施方案中,所述R11为H。
在一些实施方案中,所述R12为H、F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基、-NHRC、-NH-ORC或-NHC(O)RC;所述RC的定义如前所述。
在一些实施方案中,所述R12为H。
在一些实施方案中,所述W1为O。
在一些实施方案中,所述W2为O。
在一些实施方案中,所述的如式I所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐为式II所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,R1为H、-OH、-NH2、RA、-NH-RA、-NH-C(O)-RA或-O-RA;
R2为H、CN或RB;
R3为H、C1-6烷基、C2-6烯基或C2-6炔基;所述R3为未取代,或者选择性被1~3个R9取代在任意位置;
R4为H、C1-6烷基、C2-6烯基、C2-6炔基、C6-10芳基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基;所述R4为未取代,或者选择性被1~3个R9取代在任意位置;
所述R3和R4为独立取代基,或者R3和R4与其共同连接的碳原子一起形成C3-10环烷基或3-10元杂环烷基;所述C3-10环烷基或3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
R5为氢、卤素、氰基或C1-4烷基;
R6、R7和R8分别独立地为H、卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC或-NHS(O)2RC;
R6和R7分别为独立取代基,或者R6和R7与其连接的原子一起形成杂芳基或杂环烷基;所述杂芳基或杂环烷基为未取代,或者选择性被1~3个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC、-C(O)RC和-C(O)N(RC)2的取代基取代在任意位置;
每个RA独立地为C1-8烷基、C2-8烯基或C2-8炔基;所述RA为未取代,或者选择性被1~3个选自卤素、-OH、-NH2、氧代基、C1-3烷氧基和C1-3烷氨基的取代基取代在任意位置;
每个RB独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基或-(CH2)n-(3-8元杂环烷基);所述RB为未取代,或者选择性被1~3个R9取代在任意位置;
每个RC独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基或-(CH2)n-(3-8元杂环烷基);所述RC为未取代,或者选择性被1~3个R10取代在任意位置;
每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、-C(O)Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基;
每个Ra独立地为C1-6烷基或C2-6烯基;
n为1、2、3或4。
以下所述的如式II所述的所有实施方案、及任意实施方案的组合均包含在本发明如式II所示的结构式的范围中。
在一些实施方案中,所述的如式II所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐里某些基团的定义可如下所述,未描述的基团可如上任一方案所述:
其中,R2为H或RB;
每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,所述RA为C1-6烷基或C2-6烯基;所述RA为未取代,或者选择性被1~3个选自F、Cl、-OH、-NH2、=O、-OCH3和-N(CH3)2的取代基取代在任意位置。
在一些实施方案中,所述RB为C1-6烷基(例如:甲基、乙基、正丙基、异丙基)、C2-6烯基(例如:烯丙基)、C3-6环烷基(例如:环丙基)、苯基或5-6元杂芳基;所述RB为未取代,或者选择性被1~3个R9取代在任意位置;R9的定义如前所述。
在一些实施方案中,所述RC独立地为C1-6烷基、C2-6烯基、苯基、5-6元杂芳基、C3-6环烷基、3-6元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-6环烷基或-(CH2)n-(3-6元杂环烷基);所述RC为未取代,或者选择性被1~3个R10取代在任意位置;其中n优选为1、2或3;R10的定义如前所述。
在一些实施方案中,所述RC独立地为C1-6烷基或C3-6环烷基;所述RC为未取代,或者选择性被1~3个R10取代在任意位置;其中R10的定义如前所述。
在一些实施方案中,所述RC独立地为C1-6烷基(例如:甲基、乙基、正丙基、异丙基或叔丁基)或C3-6环烷基(例如:环丙基)。
在一些实施方案中,每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基;
在一些实施方案中,所述R9为H、-NH2、-OH、F、Cl、=O、-NHC(O)-C2-6烯基、-C(O)-C2-6烯基、-NHS(O)2-C2-6烯基、C1-4烷基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,所述R9为H、-NH2、-OH、F、Cl、=O、-NHC(O)-C2-6烯基、-NHS(O)2-C2-6烯基、C1-4烷基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,所述R9为H、F、Cl、=O、-NHC(O)-C2-6烯基或C1-4烷基。
在一些实施方案中,所述R10为H、-CN、-NH2、-OH、F、Cl、=O、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
在一些实施方案中,所述R10为H。
在一些实施方案中,所述R1为H、-OH、-OCH3、-NH2、-NH(CH3)、-NH(CH2CH3)或-NH(CH2CH=CH2)。
在一些实施方案中,所述R1为H、-OH、-NH2、-NH(CH3)或-NH(CH2CH3)。
在一些实施方案中,所述R1为H。
在一些实施方案中,R2为H或RB。
在一些实施方案中,所述R2为H、C1-6烷基、C2-6烯基、C3-6环烷基、苯基或5-6元杂芳基;所述R2为未取代,或者选择性被1~3、1~2个或1个选自F、Cl、=O、NHC(O)-C2-6烯基和C1-4烷基的取代基取代在任意位置。
在一些实施方案中,所述R3为H或C1-6烷基;所述R3为未取代,或者选择性被1~3、1~2或1个R9取代在任意位置;所述R9的定义如前所述。
在一些实施方案中,所述R3为H或C1-6烷基。
在一些实施方案中,所述R3为H、甲基或乙基。
在一些实施方案中,所述R4为H、C1-6烷基、苯基、5-6元杂芳基、C3-6环烷基或3-6元杂环烷基;所述R4为未取代,或者选择性被1~3、1~2或1个R9取代在任意位置;所述R9的定义如前所述。
在一些实施方案中,所述R4为甲基、乙基、正丙基、异丙基、苯基、吡啶基、环丙基、环丁基、环戊基或环己基;所述R4为未取代,或者选择性被1~3、1~2或1个氟、氯和甲基的取代基取代在任意位置。
在一些实施方案中,所述R3和R4与其共同连接的碳原子一起形成C3-10环烷基或3-10元杂环烷基;所述C3-10环烷基或3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;所述R9的定义如前所述。
在一些实施方案中,所述R3和R4与其共同连接的碳原子一起形成C3-10环烷基,更优选为环丙基、环丁基、环戊基、环己基、2,3-二氢-1H-茚基、2,3-二氢-1H-茚基-1-酮、螺[3,2]己基或螺[3.3]庚基。
在一些实施方案中,所述R3和R4与其共同连接的碳原子一起形成3-10元杂环烷基更优选为3-8元杂环烷基,例如:四氢呋喃基、吡咯烷基、氮杂环丁基、哌啶基或1-氧代-硫杂环丁基。
在一些实施方案中,所述R5为F、Cl、-CN、-CH3或-CH2CH3。
在一些实施方案中,所述R5为F。
在一些实施方案中,所述R5为Cl。
在一些实施方案中,所述R5为-CH3。
在一些实施方案中,所述R8为H。
在一些实施方案中,所述R6为H、F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基或1-甲基-1H-吡唑基。
在一些实施方案中,所述R7为H、-NH2、-NHRC、-NH-ORC或-NHC(O)RC;RC的定义如前所述。
在一些实施方案中,所述R6和R7与其连接的原子一起形成5-6元杂芳基或杂环烷基;所述5-6元杂芳基或杂环烷基为未取代,或者选择性被1~3、1-2或1个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC和-NHC(O)RC的取代基取代在任意位置;所述RC的定义如前所述。
在一些实施方案中,所述R6和R7与其连接的原子一起形成5-6元杂芳基或杂环烷基;所述5-6元杂芳基或杂环烷基为未取代,或者选择性被1-2或1个选自F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基、-NHRC、-NH-ORC和-NHC(O)RC的取代基取代在任意位置;所述RC的定义如前所述。
在一些实施方案中,所述R11为H、F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基、-NHRC、-NH-ORC或-NHC(O)RC;所述RC的定义如前所述。
在一些实施方案中,所述R11为H。
在一些实施方案中,所述R12为H、F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基、-NHRC、-NH-ORC或-NHC(O)RC;所述RC的定义如前所述。
在一些实施方案中,所述R12为H。
在一些实施方案中,所述如式I所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,为如式III所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
X和Y分别独立地为O、NH或CH2;
R1、R2、R5、R6、R7、R8和R9的定义均如前所述。
在一些实施方案中,所述如式I所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,为如式IV所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
R1、R2、R5、R6、R7、R8和R9的定义均如前所述。
在一些实施方案中,所述如式I所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,为如式V所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
R1、R4、R5、R6、R7、R8和R9的定义均如前所述。
在一些实施方案中,所述如式I所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,为如式VI所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,R1、R4、R5、R6、R7和R8的定义均如前所述。
在一些实施方案中,所述如式I’所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,为如式VII所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
R1、R2、R5、R6、R7、R8、R9和A3的定义均如前所述。
在一些实施方案中,所述如式I’所述的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,为如式VIII所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
R1、R4、R5、R6、R7、R8、R9和A3的定义均如前所述。
在一些实施方案中,如式I所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐任选为以下化合物:
在一些实施方案中,如式I所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐任选为以下化合物:
在一些实施方案中,如式I所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐任选为以下化合物:
在一些实施方案中,如式I所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐任选为以下化合物:
在一些实施方案中,如式I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐任选为以下化合物:
在一些实施方案中,如式I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐任选为以下化合物:
本发明还提供了如式I或I’所示的化合物制备方法,其为如下任一方法:
方法1:溶剂中,碱性条件下,将X或X’和RH通过Buchwald-hartwig偶联或Ullmann偶联反应得到如式I或I’所示化合物;
其中,L为卤素或其它离去基团,例如-OTf、-OTs或-OMs,所示L优选为氯、溴或碘;R、R1、R2、R3、R4、R5、R5a、A1、A2、A3、W1和W2的定义如前所述。
方法2:溶剂中,碱性条件下,将X或X’和RH通过Buchwald-hartwig偶联反应得到如式I或I’所示化合物;
其中,L为卤素或其它离去基团,例如-OTf、-OTs或-OMs,所示L优选为氯、溴或碘;R1、R2、R3、R4、R5、R5a、A1、A2、A3、W1、W2和Cy的定义如前所述。
如方法1或2所示方法中,所述的Buchwald-hartwig偶联反应的条件和步骤可为本领域常规的偶联反应的条件和步骤,本发明特别优选以下反应条件:所述的溶剂优选1,4-二氧六环或叔丁醇;所述溶剂的用量优选5~80mL/mmol化合物X、X’、XI或XI’;所述的碱性条件下使用的碱优选为碳酸铯或叔丁醇钠;所述的碱与化合物X、X’、XI或XI’的摩尔比优选1.05:1~3:1;偶联试剂优选为Pd2(dba)3、Xantphos和/或XPhos体系或Pd2(dba)3和Ru-phos体系;所述的反应的温度优选50~120℃;所述的反应可通过TLC或LCMS进行检测,一般以化合物X、X’、XI或XI’消失时作为反应的终点,优选1~24小时;所述的反应结束后,还可通过后处理进一步纯化产物,优选包括如下步骤:将反应体系用冰水淬灭后,用溶剂稀释,分离有机相,有机相干燥,减压除去有机溶剂,残留物用常规纯化手段,例如,硅胶柱层析、Flash柱层析或prep-HPLC纯化。所述的硅胶柱层析、Flash柱层析或prep-HPLC纯化的步骤和条件可为本领域中常规纯化的步骤和条件。
如方法1所示方法中,使用Ullmann偶联反应时,所述R优选为所述的Ullmann偶联反应的条件和步骤可为本领域常规的偶联反应的条件和步骤,本发明特别优选以下反应条件:所述的溶剂优选1,4-二氧六环,所述碱优选为磷酸钾和反式-1,2-环己二胺,在碘化亚铜存在下反应得到I或I’。
所述方法1或2中,Cy中存在不参与反应的-NH2时,该-NH2优选通过保护基保护,避免有任何副反应发生。如果存在上述氨基保护基团则需要经过后续的脱保护步骤后,得到如式I、I’、I-1或I’-1所示化合物。任何合适的氨基保护基团,例如:叔丁氧羰基(Boc)基团、乙酰基、环丙酰基、均可以用于保护氨基基团。如果使用Boc作为保护基,后续的脱保护反应可以在标准条件,例如,对甲苯磺酸/甲醇体系,二氯甲烷/三氟乙酸体系、饱和的氯化氢乙醚溶液、或三氟甲磺酸三甲基硅酯/2,6-二甲基吡啶/二氯甲烷体系中进行;乙酰基、环丙酰基作为保护基,后续的脱保护反应可以在标准条件,例如,氢氧化钾(钠)/乙醇/四氢呋喃/水体系中进行;作为保护基,后续的脱保护反应可以在标准条件,例如,乙二胺/乙醇体系中进行。
方法1中,X(包括X、X-1和X-2)或X’(包括X’、X’-1和X’-2)可通过如下反应式3~4所示方法合成:
其中,Rt为H或C1-6烷基;R1为H;R2、R3、R4、R5、R5a、L、W1和W2的定义如前所述;
溶剂中(例如:乙醇,1,4-二氧六环),酸性条件下(例如:浓硫酸),将化合物XII或XII’与相应的酮、醛、缩酮后缩醛反应得到化合物X或X’。反应温度优选为70~110℃,反应时间优选为2~24小时。
其中,R2为C1-6烷基或氘代C1-4烷基(优选为甲基、乙基或氘代甲基);R1、R3、R4、R5、R5a、L、W1和W2的定义如前所述;L’为卤素或其它离去基团,例如-OTf、-OTs或-OMs,所示L优选为溴或碘;
溶剂中(例如:DMF),将化合物X-2或X’-2与R2-L’反应得到化合物X或X’。反应温度优选为70~110℃,反应时间优选为5~48小时。
所述如式I或I’所示化合物的药学上可接受的盐可通过一般的化学方法合成。
一般情况下,盐的制备可以通过游离碱或酸与等化学当量或者过量酸(无机酸或有机酸)或碱(无机碱或有机碱)在合适的溶剂或溶剂组合物中反应制得。
本发明还提供了一种药物组合物,其包括活性组分以及药学上可接受的辅料;所述活性组分包括如式I或I’所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物和药学上可接受的盐中的一种或多种。
本发明还提供了一种药物组合物,其包括治疗有效量的活性组分以及药学上可接受的辅料;所述活性组分包括如式I或I’所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物和药学上可接受的盐中的一种或多种。
所述药物组合物中,所述活性组分还可包括其它种类用于治疗由于MNK1和/或MNK2水平失常引起的相关疾病的治疗剂;所述MNK1和/或MNK2水平失常引起的相关疾病优选为癌症。
所述药物组合物中,所述活性组分还可包括癌症的其它治疗剂。
所述药物组合物中,所述药学上可接受的辅料可包括药学上可接受的载体、稀释剂和/或赋形剂。
根据治疗目的,可将药物组合物制成各种类型的给药单位剂型,如片剂、丸剂、粉剂、液体、悬浮液、乳液、颗粒剂、胶囊、栓剂和针剂(溶液及悬浮液)等,优选液体、悬浮液、乳液、栓剂和针剂(溶液及悬浮液)等。
为了使片剂形式的药物组合物成形,可使用本领域任何已知并广泛使用的赋形剂。例如,载体,如乳糖、白糖、氯化钠、葡萄糖、尿素、淀粉、碳酸钙、高岭土、结晶纤维素和硅酸等;粘合剂,如水、乙醇、丙醇、普通糖浆、葡萄糖溶液、淀粉溶液、明胶溶液,羧甲基纤维素、紫胶、甲基纤维素和磷酸钾、聚乙烯吡咯烷酮等;崩解剂,如干淀粉、藻酸钠、琼脂粉和海带粉,碳酸氢钠、碳酸钙、聚乙烯脱水山梨醇的脂肪酸酯、十二烷基硫酸钠、硬脂酸单甘酯、淀粉和乳糖等;崩解抑制剂,如白糖、甘油三硬脂酸酯、椰子油和氢化油;吸附促进剂,如季胺碱和十二烷基硫酸钠等;润湿剂,如甘油、淀粉等;吸附剂,如淀粉、乳糖、高岭土、膨润土和胶体硅酸等;以及润滑剂,如纯净的滑石,硬脂酸盐、硼酸粉和聚乙二醇等。还可以根据需要选用通常的涂渍材料制成糖衣片剂、涂明胶膜片剂、肠衣片剂、涂膜片剂、双层膜片剂及多层片剂。
为了使丸剂形式的药物组合物成形,可使用本领域任何已知的并广泛使用的赋形剂,例如,载体,如乳糖,淀粉,椰子油,硬化植物油,高岭土和滑石粉等;粘合剂,如阿拉伯树胶粉,黄蓍胶粉,明胶和乙醇等;崩解剂,如琼脂和海带粉等。
为了使栓剂形式的药物组合物成形,可使用本领域任何已知并广泛使用的赋性剂,例如,聚乙二醇,椰子油,高级醇,高级醇的酯,明胶和半合成的甘油酯等。
为了制备针剂形式的药物组合物,可将溶液或悬浮液消毒后(最好加入适量的氯化钠,葡萄糖或甘油等),制成与血液等渗压的针剂。在制备针剂时,也可使用本领域内任何常用的载体。例如,水,乙醇,丙二醇,乙氧基化的异硬脂醇,聚氧基化的异硬脂醇和聚乙烯脱水山梨醇的脂肪酸酯等。此外,还可加入通常的溶解剂、缓冲剂和止痛剂等。
本发明中,所述的组合物在药物组合物中的含量无特殊限制,可在很宽的范围内进行选择,通常可为质量百分比的5~95%,较佳的为质量百分比30~80%。
本发明中,所述药物组合物的给药方法没有特殊限制。可根据病人年龄、性别和其它条件及症状,选择各种剂型的制剂给药。例如,片剂、丸剂、溶液、悬浮液、乳液、颗粒剂或胶囊口服给药;针剂可以单独给药,或者和注射用输送液(如葡萄糖溶液及氨基酸溶液)混合进行静脉注射;栓剂为给药到直肠。
本发明还提供了所述如式I或I’所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物或药学上可接受的盐,或所述药物组合物在制备MNK1和/或MNK2抑制剂中的应用。所述的MNK1和/或MNK2抑制剂是指可以抑制MNK1和/或MNK2活性或表达(包括MNK1和/或MNK2的异常活动或过表达)。
本发明还提供了所述如式I或I’所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物或药学上可接受的盐,或所述药物组合物具有治疗或减轻肿瘤细胞生长、增殖和/或存活,不适的细胞免疫反应及其相关病症,或不适的细胞炎性反应及其相关病症。所述肿瘤细胞生长、增殖和/或存活,不适的细胞免疫反应及其相关病症,或不适的细胞炎性反应及其相关病症是由MNK1和/或MNK2介导的。
本发明还提供了所述如式I或I’所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物或药学上可接受的盐,或所述药物组合物在制备治疗、缓解和/或预防由MNK1和/或MNK2介导的相关疾病的药物中的应用。所述MNK1和/或MNK2介导的相关疾病为增殖性疾病,优选为癌症。
本发明还提供了所述如式I或I’所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物或药学上可接受的盐,或所述药物组合物在制备治疗和/或缓解癌症药物中的应用。
本发明还提供了所述如式I或I’所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物或药学上可接受的盐,或所述药物组合物在治疗和/或缓解癌症中的应用,其包括给与哺乳动物治疗有效剂量的如式(I)所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物或药学上可接受的盐,或包含其的药物组合物。
本发明还提供了所述如式I或I’所示化合物、其异构体、前药、溶剂化物、水合物、稳定的同位素衍生物或药学上可接受的盐,或所述药物组合物和一种或多种其它种类的用于治疗癌症的治疗剂和/或治疗方法联合用于治疗、缓解和/或预防由MNK1和/或MNK2介导的相关疾病。所述MNK1和/或MNK2介导的相关疾病为增值性疾病,优选为癌症。
本发明还进一步提供一种联合制剂,包括如式I或I’所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,或所述药物组合物和其它种类的用于治疗癌症的治疗剂和/或治疗方法合用。
本发明中,所述其它种类的用于治疗癌症的治疗剂可以和所述的如式I或I’所示化合物做成单一给药的治疗剂型,或者分别先后给药的治疗剂型。
本发明中,所述其它种类的用于治疗癌症的治疗剂和/或治疗方法可包括但不限于:烷化剂、拓扑酶I/II抑制剂、抗有丝分裂剂、抗代谢类药物、激素和激素类似物、抗肿瘤抗生素、小分子激酶抑制剂、小分子免疫调节剂、干扰素、单克隆抗体和放疗中的一种或多种。
本发明中,所述烷化剂可选自但不限于:顺铂、卡铂、奥沙利铂、奈达铂、氮芥、盐酸N-氧化-氮芥、环丁酸氮芥、尿嘧啶氮芥、环磷酰胺、异环磷酰胺、噻替派、卡波醌、三亚胺醌、甲苯磺酸英丙舒凡、甘露舒凡、曲奥舒凡、白消安、盐酸尼莫司汀、二溴甘露醇、美法仑、达卡巴嗪、雷莫司汀、卡莫司汀、洛莫司汀、链脲霉素、替莫唑胺、丙卡巴肼、乙烯亚胺衍生物、甲烷磺酸酯类、亚硝脲类、三氮烯类中的一种或多种。
本发明中,所述拓扑酶I/II抑制剂可选自但不限于:多柔比星、柔红霉素、表柔比星、依达比星、伊立替康、拓扑替康、鲁比替康、贝洛替康、依托泊苷、提尼泊苷、阿霉素和右雷佐生、喜树碱中的一种或多种。
本发明中,所述抗有丝分裂剂包括但不限于:紫杉醇、多西紫杉醇、聚谷氨酸紫杉醇、异长春碱、长春新碱、长春碱、长春地辛、长春利定、依托泊苷、替尼泊苷、伊沙匹隆、拉洛他塞、ortataxel、tesetaxel、tocosal和伊斯平斯中的一种或多种。
本发明中,所述抗代谢类药物可选自但不限于:叶酸拮抗剂、嘧啶类似物、嘌呤类似物、腺苷脱氨酶抑制剂,例如:甲氨蝶呤、5-氟尿嘧啶、氟脲苷、阿糖胞苷、6-巯基嘌呤、6-硫鸟嘌呤、磷酸氟达拉滨、喷司他丁和吉西他滨中的一种或多种。
本发明中,所述激素治疗剂可选自但不限于:磷雌酚、己烯雌酚、氯烯雌酚、醋酸甲羟孕酮、醋酸甲地孕酮、醋酸氯地孕酮、醋酸环丙孕酮、达那唑、地诺孕素、烯丙雌醇、孕三烯酮、诺美孕酮、通尿灵、美帕曲星、雷洛昔芬、奥美昔芬、佐美洛昔芬、安鲁米特、睾内酯、抗雌激素类、LH-RH衍生物、芳香酶抑制剂、抗雄激素类、肾上腺皮质激素类、雄激素合成抑制剂、维甲酸和延迟维甲酸代谢的药物中的一种或多种。
本发明中,所述抗肿瘤抗生素包括但不限于:放线菌素D、多柔比星、柔红霉素、博来霉素、培洛霉素、丝裂霉素C、阿柔比星、吡柔比星、表柔比星、净司他丁斯酯、伊达比星、西罗莫司和戊柔比星中的一种或多种。
本发明中,所述小分子激酶抑制剂包括但不限于:厄洛替尼、伊马替尼、阿帕替尼、尼洛替尼、克唑替尼、达沙替尼、帕唑帕尼、瑞格菲尼、鲁索利替尼、索拉菲尼、苏尼替尼、凡德他尼、维罗非尼、博舒替尼、吉非替尼、阿法替尼、阿昔替尼、达拉菲尼、达克替尼、尼达尼布、乐伐替尼、马赛替尼、米哚妥林、来那替尼、帕纳替尼、雷多替尼、曲美替尼、丙氨酸布立尼布、西地尼布、苹果酸卡博替尼、依鲁替尼、埃克替尼、西帕替尼、考比替尼和艾代拉利司中的一种或多种。
本发明中,所述单克隆抗体包括但不限于:阿伦单抗、本妥昔单抗、西妥昔单抗、利妥昔单抗、地诺单抗、依匹单抗、奥法木单抗、帕尼单抗、托西莫单抗、曲妥单抗、贝伐珠单抗、帕妥珠单抗、卡妥索单抗、埃洛妥珠单抗、依帕珠单抗、耐昔妥珠单抗、尼妥珠单抗、托珠单抗、马托珠单抗、扎鲁木单抗、阿托珠单抗、雷莫芦单抗和纳武单抗中的一种或多种。
本发明中,所述小分子免疫调节剂包括但不限于:TLR7激动剂、TLR8激动剂、TLR9激动剂、IDO抑制剂、CD73抑制剂、STING抑制剂、A2AR拮抗剂、PD-L1抑制剂中的一种或多种。
本发明中,所述用于癌症治疗的干扰素包括但不限于:干扰素α、干扰素α-2a、干扰素α-2b、干扰素β、干扰素γ-1a或干扰素γ-n1等。
本发明中,所述放疗是本领域熟知的并且包括X射线的治疗,例如伽马放射、放射药物治疗等。
本发明中,所述癌症包括转移性的和非转移性的癌症,也包括家族遗传性的和偶发性的癌症,还可包括固体肿瘤和非固体肿瘤。
本发明中,所述固体肿瘤的具体例子可包括但不限于:眼癌、骨癌、肺癌、胃癌、胰腺癌、胰岛细胞癌、乳腺癌、三阴性乳腺癌、前列腺癌、趋势抵抗性前列腺癌、脑癌(包括噁性胶质瘤、成神经管细胞瘤)、CNS癌、成胶质细胞瘤、卵巢癌、膀胱癌、尿路上皮癌、子宫颈癌、睾丸癌、肾癌(包括腺癌和肾母细胞癌)、口腔癌(包括鳞状细胞癌)、舌癌、喉癌、鼻咽癌、头颈癌、结肠癌、小肠癌、直肠癌、结直肠癌、甲状旁腺癌、甲状腺癌、食管癌、胆囊癌、胆管癌、宫颈癌、肝癌、肝细胞癌、肺癌、非小细胞肺癌、肉瘤、平滑肌肉瘤、成肌细胞瘤、肌瘤、横纹肌瘤、神经节瘤、神经上皮瘤、神经母细胞瘤、皮肤癌、黑色素瘤、恶性类癌综合症、类癌心脏病中的一种或多种。
本发明中,所述非固体肿瘤(包括血液学肿瘤)的具体例子可包括但不限于:B细胞淋巴瘤、T细胞淋巴瘤、弥漫性大B细胞淋巴瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、伯基特淋巴瘤、骨髓增生异常综合症、淋巴性白血病(包括成淋巴细胞白血病、淋巴瘤、骨髓瘤、多发性骨髓瘤、慢性淋巴性白血病(T细胞慢性淋巴性白血病、B细胞慢性淋巴性白血病)和髓性相关的白血病(包括急性髓性白血病、慢性髓性白血病)中的一种或多种。
本发明中,所述给与治疗有效剂量的如式I或I’所示化合物或药学上可接受的盐,所述治疗有效剂量根据各种因素而变化,例如包括所用特定化合物的活性、该化合物的代谢稳定性和作用时长、患者年龄、体重、健康状况、性别、给药方式和时间、吸收代谢特性、具体疾病或病症的严重程度等因素。“治疗有效量”是指当给与哺乳动物足以提供对于该哺乳动物中MNK1和/或MNK2相关病症或疾病的有效治疗的量。构成治疗有效量的本发明化合物的量需要根据化合物、病症以及其严重性、给药方式、待治疗哺乳动物的年龄的变化而变化,但可以由本领域技术人员根据其所掌握的知识和本发明内容来常规地确定。
本发明中,所述哺乳动物优选为人。
本发明中,除非另有说明,术语“被1~3个基团取代在任意位置”是指基团上所指定的1个、2个或3个原子的任何1个、2个或3个氢原子用所指定的基团取代,条件是不超过指定原子的正常化合价,所述取代均为本领域常见的合理取代。
本发明中,当与取代基的键合显示与连接环中两个原子的键合相交时,那么这样的取代基可键合在环上的任何可键合的环原子。
除非另有说明,在本发明说明书和权利要求书中出现的以下术语具有下述含义:
术语“烷基”是指包含1-20个碳原子的饱和直链或支链烃基,优选1-10个碳原子,更优选1-8,1-6,1-4,1-3个碳原子,烷基的代表性例子包括但不限于:甲基、乙基、正丙基、异丙基、正丁基、仲丁基、叔丁基、异丁基、戊基、己基、庚基、辛基、壬基、癸基、4,4-二甲基戊基、2,2,4-三甲基戊基、十一烷基、十二烷基,及它们的各种异构体等。
术语“氘代烷基”是指氘原子任意取代的烷基,本发明所述氘代烷基优选被氘原子全取代的烷基,例如-CD3、-C2D5。
术语“环烷基”是指包含3-20个碳原子的饱和或部分不饱和(包含1或2个双键)的单环或多环基团。“环烷基”优选C3-10环烷基,更优选C3-8单环烷基、C3-6单环烷基,所述“单环烷基”的代表性例子包括但不限于:环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环癸基、环十二烷基、环己烯基。“多环环烷基”包括“桥环基”、“稠合环烷基”和“螺环烷基”,“桥环基”的代表性例子包括但不限于:冰片基、双环[2.2.1]庚烯基、双环[3.1.1]庚烷基、双环[2.2.1]庚烷基、双环[2.2.2]辛烷基、双环[3.2.2]壬烷基、双环[3.3.1]壬烷基、双环[4.2.1]壬烷基和金刚烷基等。“稠合环烷基”包含稠合到苯基、环烷基或杂芳基上的环烷基环,稠合环烷基包括但不限于:苯并环丁烯基、2,3-二氢-1H-茚基、5,6-二氢-4H-环戊基[B]噻吩基、十氢萘基等。“螺环烷基”是指两个单环环烷基共用一个碳原子形成的双环基团,螺环烷基包括但不限于:螺[3,3]庚基、螺[3,2]己基、螺[2,5]辛基、螺[2,4]庚基、螺[4,5]癸基等。“C3-10环烷基”是指包含3-10个碳原子的环烷基;“C3-8环烷基”是指包含3-8个碳原子的环烷基。“C3-6环烷基”是指包含3-6个碳原子的环烷基。单环环烷基或多环环烷基可以通过环上任意的1个或2个碳原子链接到母体分子上。
术语“杂环烷基”指由碳原子以及选自氮、氧或硫等杂原子组成的饱和或部分不饱和(包含1或2个双键)的非芳香环状基团,此环状基团可为单环或多环基团,在本发明中,杂环烷基中杂原子个数优选1、2、3或4,杂环烷基中的氮、碳或硫原子可任选地被氧化。氮原子可任选进一步被其他基团取代而形成叔胺或季铵盐。“单环杂环烷基”优选3-10元单环杂环烷基,更优选3-8元单环杂环烷基。例如:氮丙啶基、四氢呋喃基、吗啉-4-基、硫代吗啉基、硫代吗啉-S-氧化物-4-基、哌啶基、吡咯烷基、哌嗪基、硫杂环丁烷1-氧化物、1-氧代-硫杂环丁基等。“多环杂环烷基”包括“稠合杂环烷基”、“螺杂环基”和“桥杂环烷基”。“稠合杂环烷基”包含稠合到苯基、环烷基、杂环烷基或杂芳基的单环杂环烷基环,稠合杂环烷基包括但不限于:2,3-二氢苯并呋喃基、1,3-二氢异苯并呋喃基、二氢吲哚基、2,3-二氢苯并[b]噻吩基、二氢苯并哌喃基、1,2,3,4-四氢喹啉基、6,7-二氢-5H-吡咯并[2,3-d]嘧啶基、等。“螺杂环基”是指两个杂环烷基或一个环烷基和一个杂环烷基共用一个碳原子形成的双环基团,螺杂环基包括但不限于:5-氮杂[2.5]辛基、4-氮杂[2.5]辛基、4-氮杂[2.4]庚基等。所述9-10元杂环烷基优选为9-10元稠合杂环烷基。单环杂环烷基和多环杂环烷基可以通过环上任意的1个或2个环原子链接到母体分子上。上述环原子特指组成环骨架的碳原子和/或氮原子。
术语“环烷基烷基”是指环烷基与母核结构之间通过烷基连接。由此,“环烷基烷基”包含上述烷基和环烷基的定义。
术语“杂环烷基烷基”是指杂环烷基与母核结构之间通过烷基连接。由此,“杂环烷基烷基”包含上述烷基和杂环烷基的定义。
术语“烷氧基”指通过氧桥连接的具有所述碳原子数目的环状或者非环状烷基,包含烷基氧基、环烷基氧基和杂环烷基氧基。由此,“烷氧基”包含上述烷基、杂环烷基和环烷基的定义。
术语“烯基”指含有至少1个碳碳双键的直链、支链或者环状非芳香烃基。其中可以存在1-3个碳碳双键,优选存在1个碳碳双键。术语“C2-4烯基”是指具有2-4个碳原子的烯基,术语“C2-6烯基”是指具有2-6个碳原子的烯基,包括乙烯基、丙烯基、丁烯基、2-甲基丁烯基和环己烯基。
术语“炔基”是指含有至少1个碳碳三键的直链、支链或者环状烃基。其中可以存在1-3个碳碳三键,优选存在1个碳碳三键。术语“C2-6炔基”是指具有2-6个碳原子的炔基,包括乙炔基、丙炔基、丁炔基和3-甲基丁炔基。
术语“芳基”是指任何稳定的6-20元单环或多环芳香族基团,例如:苯基、萘基、四氢萘基、2,3-二氢化茚基或联苯基等。
术语“杂芳基”是指至少1个环上的碳原子被选自氮、氧或硫的杂原子置换所形成的芳香环基团,其可为5-7元单环杂芳基或7-20稠合杂芳基。所述“稠合杂芳基”中至少有一个环为杂芳环,所述“杂芳环”优选5-6元单环杂芳基和9-12或9-10元稠合杂芳基。在本发明中,杂原子个数优选1、2或3,5-6元杂芳基的例子包括但不限于:吡啶基、嘧啶基、哌嗪基、哒嗪-3(2H)-酮基、呋喃基、噻吩基、噻唑基、吡咯基、咪唑基、吡唑基、噁唑基、异噁唑基、1,2,5-噁二唑基、1,2,4-噁二唑基、1,3,4-噁二唑基、1,3,4-噻二唑、1,2,4-三氮唑基、1,2,3-三氮唑基、四氮唑基等;9-10元稠合杂芳基的例子包括但不限于:吲唑基、异吲唑基、吲哚基、异吲哚基、苯并呋喃基、苯并噻吩基、苯并噻唑基、苯并噁唑基、喹啉基、异喹啉基、异喹啉酮基、喹唑啉基、7H-吡咯并[2,3-d]嘧啶基、1H-吡唑并[3,4-d]嘧啶、噻唑并[5,4-d]嘧啶、9H-嘌呤、噻唑并[4,5-d]嘧啶-2(3H)-酮基、3H-[1,2,3]三氮唑并[4,5-d]嘧啶基、5,6,7,8-四氢苯并[4,5]噻唑并[2,3-d]嘧啶基、6,7-二氢-5H-环戊烷并[4,5]噻唑并[2,3-d]嘧啶基等。
术语“芳基烷基”是指芳基与母核结构之间通过烷基连接。由此,“芳基烷基”包含上述烷基和芳基的定义。
术语“杂芳基烷基”是指杂环烷基与母核结构之间通过烷基连接。由此,“杂芳基烷基”包含上述烷基和杂芳基的定义。术语“卤素”表示氟、氯、溴或碘。
术语“卤代烷基”是指被卤素任意取代的烷基。由此,“卤代烷基”包含以上卤素和烷基的定义。
术语“卤代烷氧基”是指被卤素任意取代的烷氧基。由此,“卤代烷氧基”包含以上卤素和烷氧基的定义。
术语“酯基”是指-C(O)OR’,R’为C1-6烷基。
术语“酰胺基”是指-C(O)N(R”)2,R”为氢、C1-6烷基或C2-6烯基。
术语“羧基”是指-C(O)OH。
术语“酰基”是指-C(O)R”’,R”’为C1-6烷基、C2-6烯基或C3-8环烷基。
术语“硝基”是指-NO2。
术语“氧代基”是指=O。
术语“氰基”是指-CN。
术语“羟基”是指-OH。
术语“巯基”是指-SH。
术语“氨基”是指-NH2。
术语“烷氨基”是指氨基上至少一个氢原子被烷基所取代,包括但不限于:-NHCH3、-N(CH3)2、-N(CH3)(CH2CH3)、-N(CH2CH3)2。由此,“烷氨基”包含上述烷基和氨基的定义。
符号“=”表示双键;
本发明所述“室温”是指15-30℃。
所述的稳定的同位素衍生物包括:式I中任意的氢原子被1-5个氘原子取代得到的同位素取代衍生物(例如:R2为CD3)、式I中任意的碳原子被1-3个碳14原子取代得到的同位素取代衍生物或式I或I’中任意的氧原子被1-3个氧18原子取代得到的同位素取代衍生物。
所述的“前药”是指化合物在体内代谢后转换成原始活性化合物。代表性地讲,前药为非活性物质,或者比活性母体化合物活性小,但可以提供方便的操作、给药或者改善代谢特性。
本发明所述的“药学上可接受的盐”在Berge,et al.,“Pharmaceuticallyacceptable salts”,J.Pharm.Sci.,66,1-19(1977)中有讨论,并对药物化学家来说是显而易见,所述的盐是基本上无毒性的,并能提供所需的药代动力学性质、适口性、吸收、分布、代谢或排泄等。本发明所述化合物可以具有酸性基团、碱性基团或两性基团,典型的药学上可接受的盐包括通过本发明化合物和酸反应制备得到的盐,例如:盐酸盐、氢溴酸盐、硫酸盐、焦硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、磷酸盐、磷酸一氢盐、磷酸二氢盐、偏磷酸盐、焦磷酸盐、硝酸盐、乙酸盐、丙酸盐、癸酸盐、辛酸盐、甲酸盐、丙烯酸盐、异丁酸盐、己酸盐、庚酸盐、草酸盐、丙二酸盐、琥珀酸盐、辛二酸盐、苯甲酸盐、甲基苯甲酸盐、邻苯二甲酸盐、马来酸盐、甲磺酸盐、对甲苯磺酸盐、(D,L)-酒石酸盐,柠檬酸盐,马来酸盐,(D,L)-苹果酸盐,富马酸盐,乳酸盐、三氟甲磺酸盐、萘-1-磺酸盐、扁桃酸盐、丙酮酸盐、硬脂酸盐、抗坏血酸盐、水杨酸盐。当本发明化合物含有酸性基团时,其药学上可接受的盐还可以包括:碱金属盐,例如钠或钾盐;碱土金属盐,例如钙或镁盐;有机碱盐,例如和氨、烷基氨类、羟基烷基氨类、氨基酸(赖氨酸、精氨酸)、N-甲基葡糖胺等形成的盐。
本发明所述“异构体”是指本发明的式I或I’化合物可以有不对称中心和外消旋体、外消旋混合物和单个非对映异构体,所有这些异构体,包括立体异构体、几何异构体、阻转异构体、互变异构体均包含在本发明中。在本发明中,式I或I’化合物或其盐以立体异构的形式(例如,其含有一个或多个不对称碳原子)存在时,单独的立体异构体(对映异构体和非对映异构体)以及它们的混合物包括在本发明的范围内。本发明还包括式I或I’表示的化合物或盐的单独异构体,以及与其中一个或多个手性中心反转的异构体的混合物。本发明的范围包括:立体异构体的混合物,以及纯化的对映异构体或对映异构体/非对映异构体富集的混合物。本发明包括所有对映异构体及非对应异构体所有可能的不同组合的立体异构体的混合物。本发明包括上文定义的所有具体基团的立体异构体的全部组合和子集。本发明还包括式I或I’化合物或其盐的几何异构体,所述几何异构体包括顺反异构体。本发明还包括式I或I’化合物或其盐的互变异构体,所述互变异构体是指从分子的一个原子到同一个分子的另一个原子的质子迁移。例如,当W1为=O且R1为H时,本发明提供如式I或I’所示化合物的互变异构体,如下所示:
在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
本发明所有化合物的结构可通过核磁共振(1H NMR)和/或质谱检测(MS)鉴定。
1H NMR化学位移(δ)以ppm记录(10-6)。NMR通过Bruker AVANCE-400光谱仪进行。合适的溶剂是氘代氯仿(CDCl3),氘代甲醇(CD3OD),氘代二甲亚砜(DMSO-d6),四甲基硅烷作为内标(TMS)。
低分辨率质谱(MS)由Utimate 3000 HPLC-MSQ Plus MS质谱仪测定,使用Kinetex2.6u C18 100A(50×4.6mm)LCMS-02-001,ESI源,梯度洗脱条件:95%溶剂A和5%溶剂B(小于1.5分钟或大于3分钟),然后5%溶剂A和95%溶剂B(1.5分钟到3分钟),百分数为某一溶剂占总溶剂体积的体积百分数。溶剂A:10mM的碳酸氢铵水溶液;溶剂B:乙腈。
本发明化合物及中间体的纯化可以使用常规的制备硅胶板或使用快速分离机进行分离纯化,洗脱体系可以是乙酸乙酯/石油醚体系或二氯甲烷/甲醇体系。还可以使用制备HPLC进行分离。
高效液相色谱仪(prep-HPLC)使用GilsonGX-281制备液相色谱,色谱柱为xtimateC18,10um,21.2×250mm。分离条件1:洗脱梯度,流动相B从10%到25%,洗脱时间5分钟,流动相B从25%到45%,洗脱时间15分钟,流动相A:10mM碳酸氢铵水溶液,流动相B:乙腈;分离条件2:洗脱梯度,流动相B从15%到30%,洗脱时间5分钟,流动相B从30%到50%,洗脱时间15分钟,流动相A:0.05%的盐酸水溶液,流动相B:乙腈;分离条件3:流动相B从15%到20%,洗脱时间5分钟,流动相B从20%到40%,洗脱时间15分钟,流动相A:0.05%的盐酸水溶液,流动相B:乙腈;分离条件4:流动相B从10%到20%,洗脱时间5分钟,流动相B从20%到45%,洗脱时间15分钟,流动相A:0.05%的盐酸水溶液,流动相B:乙腈;分离条件5:流动相B从5%到10%,洗脱时间5分钟,流动相B从10%到30%,洗脱时间15分钟,流动相A:0.05%的盐酸水溶液,流动相B:乙腈;分离条件6:流动相B从10%到10%,洗脱时间5分钟,流动相B从10%到35%,洗脱时间15分钟,流动相A:0.05%的盐酸水溶液,流动相B:乙腈。检测波长:214nm、254nm和/或262nm;流速:15.0mL/分钟。
薄层硅胶板(prep-TLC)是烟台黄海HSGF254或青岛GF254硅胶板。
快速分离机(Flash柱层析)(Flash system/CheetahTM)使用的是AgelaTechnologies MP200,配套使用的分离柱为Flash columm Silica-CS(80g),CatNo.CS140080-0。
本发明所有化合物可通过超高效液相色谱仪进行分析,超高效液相色谱仪(UPLC)使用Waters ACQUITY Hclass平台,色谱柱为:Waters ACQUITY UPLC BEH Shield RP182.1mm*100mm,1.7μm,流动相A:乙腈,流动相B:5mm磷酸二氢钾水溶液(用磷酸调pH值至2.5)。梯度洗脱时间15分钟,流速:0.4mL/min,检测波长:214nm&254nm;柱温:40℃;进样量1μL;梯度洗脱条件如下表1:
表1
时间(分钟) | 流速相A(%) | 流速相B(%) |
0.00 | 10 | 90 |
5.00 | 40 | 60 |
7.00 | 90 | 10 |
13.00 | 90 | 10 |
13.10 | 10 | 90 |
15.00 | 10 | 90 |
本发明所涉及的手性化合物或中间体可通过超临界流体色谱仪(SFC)进行分离和分析。
手性拆分使用超临界流体色谱仪SFC-80(Thar,Waters),流速为80g/min,柱温为35℃。检测波长为214和/或254nM。手性拆分条件:手性柱IC 20×250mm,10um(Daicel),流动相为二氧化碳/甲醇(含有0.2%的氨甲醇溶液)=50/50,样品浓度:5mg/mL(甲醇),进样量:4mL。
本发明化合物的手性分析使用超临界流体色谱分析仪SFC Method Station(Thar,Waters),流速为4mL/min,柱温为40℃;检测波长为214和/或254nM。手性分析条件:手性柱Cellulose-SC 4.6×100mm,5um(YMC),流动相为二氧化碳/甲醇(含有0.2%的氨甲醇溶液)=65/35。
本发明实施例中使用的缩写含义如下:
NaBH4:硼氢化钠、TFA:三氟乙酸、Cs2CO3:碳酸铯、Boc2O:二叔丁基二碳酸酯、DMAP:4-二甲氨基吡啶、Xantphos:4,5-双二苯基膦-9,9-二甲基氧杂蒽、Ruphos:2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯、XPhos:2-二环己基磷-2,4,6-三异丙基联苯、Pd2(dba)3:三(二亚苄基丙酮)二钯、THF:四氢呋喃、PE:石油醚、EtOAc:乙酸乙酯、DCM:二氯甲烷、DMF:N,N-二甲基甲酰胺、MeOH:甲醇、EtOH:乙醇、MTBE:甲基叔丁基醚、DMSO:二甲亚砜、HOBT:1-羟基苯并三唑、EDCI:1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐。
中间体的合成:
中间体1.1的合成
步骤1:向5-溴-3-甲基吡啶-2-羧酸(50g,231mmol)的乙醇(250mL)溶液中,滴加浓硫酸(12.5mL)。反应液于95℃下搅拌过夜,减压浓缩。残留物用DCM(500mL)溶解,并用饱和碳酸钠水溶液调节pH为7。分离有机相,水相用DCM萃取。合并有机相,分别用水,饱和食盐水洗涤。无水硫酸钠干燥,过滤,滤液减压浓缩得到5-溴-3-甲基吡啶-2-甲酸乙酯(55.1g)为浅黄色油状物。m/z:[M+H]+276.0;1H NMR(400MHz,DMSO-d6):δ8.61(s,1H),8.12(s,1H),4.33(q,J=7.2Hz,2H),2.44(s,3H),1.31(t,J=7.2Hz,3H).
步骤2:冰浴条件下,向步骤1所得产物(55g,225mmol)的DCM(280mL)溶液中分批加入过氧化脲(37.1g,394mmol),然后缓慢滴加三氟乙酸酐(55.6mL,394mmol)。加毕,反应体系升至室温搅拌5小时。将反应液倒入冰水中,用DCM(2×200mL)萃取。合并有机相,用饱和食盐水洗涤、无水硫酸钠干燥,过滤、滤液减压浓缩得到5-溴-2-(乙氧羰基)-3-甲基吡啶1-氧化物(58g)为黄褐色油状物。m/z:[M+H]+260.0,262.0.
步骤3:向步骤2所得产物(58g,223mmol)的DMF(200mL)溶液中缓慢滴加三氟乙酸酐(55mL,390mmol)。加毕,反应体系加热至40℃搅拌1小时。将反应液倒入冰水中,有大量白色固体产生,过滤。滤饼依次用水和MTBE洗涤。滤饼真空干燥得到5-溴-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酸乙酯(25g)为白色固体。m/z:[M+H]+260.0,262.0.
步骤4:将步骤3所得产物(5.6g,21.5mmol)和Cs2CO3(28.1g,86.1mmol)的DMF(50mL)溶液先搅拌15分钟,再向其中加入O-(二苯基氧膦基)羟胺(10g,43.1mmol)。加毕,反应体系室温搅拌2小时。向反应液中加入水(150mL),用EtOAc(50mL×4)萃取,合并有机相后依次用水和饱和食盐水洗涤、无水硫酸钠干燥,过滤,滤液减压浓缩得到1-氨基-5-溴-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酸乙酯(6g,粗品)为黄色油状液体。m/z:[M+H]+275.0.
步骤5:将步骤4所得产物(500mg,粗品)和氨甲醇溶液(7mol/L,10mL)加入封管中,加热至85℃,搅拌2天。然后将反应液冷却至室温并减压浓缩,得到1-氨基-5-溴-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酰胺(500mg,粗品)为黄色固体。m/z:[M+H]+246.0;1H NMR(400MHz,DMSO-d6):δ7.96(s,1H),7.91(s,1H),7.86(s,1H),5.85(s,2H),2.02(s,3H).
步骤6:将步骤5所得产物(400mg,粗品)和环己酮(1.6g,16.3mmol)加入至1,4-二氧六环(10mL)中,反应液在95℃下搅拌2小时,缓慢冷却至室温,反应液剧烈搅拌下向其中加入浓硫酸(0.1mL),继续搅拌1.5小时。将反应液减压浓缩,残留物用乙酸乙酯稀释,有机相分别用水和饱和食盐水洗涤、无水硫酸钠干燥,过滤,滤液减压浓缩,残留物用prep-TLC(DCM/MeOH=20/1)纯化得到7'-溴-5'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪-4',8'(1'H,3'H)-二酮(中间体1.1,400mg)为类白色固体。m/z:[M+H]+326.0;1H NMR(400MHz,DMSO-d6):δ9.17(s,1H),7.92(s,1H),3.57(s,1H),2.38(s,3H),1.70-1.40(m,10H).
中间体1.2-1.6的合成
利用中间体1.1的合成方法,将步骤1中5-溴-3-甲基吡啶-2-羧酸替换为相应的取代的3,5-二溴吡啶-2-羧酸、步骤6中的环己酮替换为相应的酮得到中间体1.2-1.6:
表2
中间体1.8的合成
步骤1:将1-氨基-5-溴-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酸乙酯(300mg,1.09mmol)的丙酮(5mL)和1,4-二氧六环(10mL)溶液加入到封管中,反应体系在110℃下搅拌2天。冷却后将反应液直接浓缩得到5-溴-3-甲基-6-氧代-1-(丙-2-亚基氨基)-1,6-二氢吡啶-2-甲酸乙酯(370mg)为黄色液体。m/z:[M+H]+315.0,317.0.
步骤2:将硼氢化钠(126mg,3.33mmol)加入到步骤1所得产物(350mg,粗品)的MeOH(10mL)溶液中。反应体系室温搅拌3天。将反应液倒入水中,用乙酸乙酯(3×30mL)萃取,有机相用无水硫酸钠干燥、过滤,滤液减压浓缩得到5-溴-1-(异丙基氨基)-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酸乙酯(70mg)为黄色液体。m/z:[M+H]+317.0,319.0.
步骤3:将一水合氢氧化锂(26mg,0.63mmol)加入到步骤2所得产物(50mg,0.16mmol)的MeOH/THF/水(5mL/5mL/5mL)混合溶液中。反应体系加热到50℃搅拌16小时。将反应液浓缩后倒入水中,用1N HCl调pH=5,水相用乙酸乙酯(3×30mL)萃取,有机相用无水硫酸钠干燥、过滤,滤液减压浓缩得到5-溴-1-(异丙基氨基)-3-甲基-6-氧代-1,6-二氢吡啶-2-羧酸(45mg)为黄色固体。m/z:[M+H]+289.0,291.0.
步骤4:将步骤3所得产物(45mg,0.16mmol)加到氯化亚砜(5mL)和DCM(5mL)中,反应体系加热到50℃搅拌8小时,将反应液浓缩后加入氨甲醇(5mL,7M),反应体系在室温下搅拌2小时后浓缩得到5-溴-1-(异丙基氨基)-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酰胺(40mg)为棕色固体。m/z:[M+H]+288.0,290.0.
步骤5:将浓硫酸(2滴)加入到步骤4所得产物(40mg,粗品)和环己酮(136mg,1.39mmol)的1,4-二氧六环(10mL)溶液中。反应液加热到95℃搅拌16小时。冷却后将反应液浓缩,向残留物中加入水和石油醚打浆,过滤、滤饼真空干燥得到7'-溴-1'-异丙基-5'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪-4',8'(1'H,3'H)-二酮(中间体1.8,50mg)为棕色固体。m/z:[M+H]+368.0,370.0.
中间体1.9的合成
步骤1:将醋酸铜(1.98g,10.9mmol)和吡啶(1.15g,15.5mmol)加入到1-氨基-5-溴-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酸乙酯(2.0g,7.27mmol)、3-硝基苯硼酸(2.43g,14.5mmol)的DCM(10mL)溶液中,反应体系在45℃下搅拌16小时。将反应体系冷却至室温后倒入水中,水相用DCM(3×30mL)萃取,合并有机相后用无水硫酸钠干燥,过滤、滤液减压浓缩,残留物用Flash柱层析(PE/EtOAc=1/1)纯化得到5-溴-3-甲基-1-((3-硝基苯基)氨基)-6-氧代-1,6-二氢吡啶-2-甲酸乙酯(700mg)为黄色固体。m/z:[M+H]+395.8.
步骤2:将一水合氢氧化锂(297mg,7.07mmol)加入到步骤1所得产物(700mg,1.77mmol)的MeOH/THF/水(3mL/3mL/3mL)混合溶液中,反应体系室温下搅拌4小时。将反应液浓缩后倒入水中,用1N盐酸调pH=3,水相用EtOAc(3×10mL)萃取,合并有机相后用无水硫酸钠干燥,过滤、滤液减压浓缩得到5-溴-3-甲基-1-((3-硝基苯基)氨基)-6-氧代-1,6-二氢吡啶-2-羧酸(650mg)为黄色固体。m/z:[M+H]+367.8.
步骤3:将步骤2所得产物(650mg,1.77mmol)加到氯化亚砜(5mL)和DCM(5mL)中,反应体系在50℃下搅拌4小时。将反应液浓缩后,加入氨甲醇溶液(7M,5mL),反应体系在室温下搅拌1小时,减压浓缩得到5-溴-3-甲基-1-((3-硝基苯基)氨基)-6-氧代-1,6-二氢吡啶-2-甲酰胺(800mg)为黄色固体。m/z:[M+H]+366.8.
步骤4:将浓硫酸(0.1mL)滴加到步骤3所得产物(400mg,1.09mmol)和环丁酮(611mg,8.72mmol)的1,4-二氧六环(10mL)溶液中,反应体系在50℃下搅拌4小时。冷却后将反应液浓缩,加入水中过滤得到固体,再用乙醇(5mL)打浆、过滤、滤饼真空干燥得到7'-溴-5'-甲基-1'-(3-硝基苯基)螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮(中间体1.9,294mg)为黄色固体。m/z:[M+H]+418.8.
中间体1.10的合成
将1-氨基-5-溴-3-氯-6-氧代-1,6-二氢吡啶-2-甲酰胺(200mg,0.75mmol)和3,3-二甲基环丁酮(295mg,3.0mmol)加入到无水乙醇(5mL)中,反应体系加热至90℃,缓慢滴加浓硫酸(6滴)。该混合溶液加热搅拌4小时,有白色固体析出。减压浓缩,将固体分散到饱和碳酸氢钠水溶液中,过滤。滤饼分别用水和石油醚洗涤。滤饼真空干燥得到7'-溴-5'-氯-3,3-二甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮(中间体1.10,240mg)为浅黄色固体。m/z:[M+H]+346.0,348.0;1H NMR(400MHz,DMSO-d6):δ9.76(s,1H),8.15(s,1H),7.33(s,1H),2.12-1.94(m,4H),1.22(s,3H),1.14(s,3H).
中间体1.11-1.14的合成
利用中间体1.10的合成方法,将3,3-二甲基环丁酮替换为相应的酮得到中间体1.11-1.14:
表3
中间体2.1的合成
步骤1:将化合物1.4(200mg,0.6mmol),碘甲烷(445mg,3mmol)和DMF(2mL)加入封管中,反应体系在105℃下搅拌16小时。然后将反应液减压浓缩,残留物用prep-TLC(EtOAc)纯化得到7'-溴-5'-氯-1'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮(200mg)为黄色固体。m/z:[M+H]+331.9.
步骤2:氮气保护下,将步骤1所得产物(60mg,0.18mmol),氨基甲酸叔丁酯(42mg,0.36mmol),Pd2(dba)3(3mg),Xantphos(3mg),XPhos(3mg),Cs2CO3(118mg,0.36mmol)和叔丁醇(1.6mL)的混合物在85℃下搅拌24小时。将反应液减压浓缩,残留物用prep-TLC(PE/EtOAc=1/1)纯化得到(5'-氯-1'-甲基-4',8'-二氧代-1',3',4',8'-四氢螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-7'-基)氨基甲酸叔丁酯(40mg)为白色固体。m/z:[M+H]+368.9.
步骤3:冰浴条件下,向步骤2所得产物(40mg,0.11mmol)的DCM(0.3mL)溶液中滴加TFA(0.3mL),加毕,反应液室温搅拌16小时。将反应液减压浓缩,残留物用DCM稀释,加入碳酸氢钠固体调节pH=7,搅拌约20分钟,过滤,滤液减压浓缩得到7'-氨基-5'-氯-1'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮(中间体2.1,40mg)为黄色固体。m/z:[M+H]+269.0.
中间体3.1和3.2的合成
将1-氨基-5-溴-3-氯-6-氧代-1,6-二氢吡啶-2-甲酰胺(100mg,0.4mmol)、5-氯-2-戊酮(113mg,0.9mmol)和浓硫酸(1滴)加入至乙醇(1mL)中,80℃下搅拌8小时。缓慢冷却至室温,过滤,滤饼真空干燥得到7-溴-5-氯-2-(3-氯丙基)-2-甲基-2,3-二氢-1H-吡啶并[2,1-f][1,2,4]三嗪-4,8-二酮(中间体3.1)和8-溴-6-氯-3a-甲基-2,3,3a,4-四氢-1H-吡啶并[2,1-f]吡咯并[1,2-b][1,2,4]三嗪-5,9-二酮(中间体3.2)的混合物(85mg,3.1/3.2=1/2.7)为白色固体。m/z:[M+H]+368.0,332.0.
中间体3.3的合成
将1-氨基-5-溴-3-氯-6-氧代-1,6-二氢吡啶-2-甲酰胺(150mg,0.56mmol)和6-氯-2-己酮(227mg,1.69mmol)的乙醇(6mL)溶液在封管中110℃下搅拌16小时。反应液冷却至室温后浓缩,残留物用乙酸乙酯溶解,有机相用水洗,分离有机相并用无水硫酸钠干燥,过滤,滤液减压浓缩得到9-溴-7-氯-4a-甲基-1,2,3,4,4a,5-六氢二吡啶并[1,2-b:2',1'-f][1,2,4]三嗪-6,10-二酮(中间体3.3,150mg)棕色固体。m/z:[M+H]+345.8.
中间体3.4-3.6的合成
利用中间体3.3的合成方法,用1-氨基-5-溴-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酰胺和相应的氯代酮反应得到中间体3.4-3.6:
表4
中间体4.1的合成
将1-氨基-5-溴-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酰胺(100mg,0.4mmol)、乙酰丙酸甲酯(264mg,2mmol)和浓硫酸(1滴)加入至1,4-二氧六环(1mL)中,95℃下搅拌4小时。缓慢冷却至室温,过滤,滤液减压浓缩得到8-溴-3a,6-二甲基-2,3,3a,4-四氢-1H-吡啶并[2,1-f]吡咯并[1,2-b][1,2,4]三嗪-1,5,9-三酮(中间体4.1,80mg)为黄色油状物。m/z:[M+H]+326.0.
中间体5.1的合成
将1-氨基-5-溴-3-甲基-6-氧代-1,6-二氢吡啶-2-甲酰胺(60mg,0.2mmol),三氯化锑(6mg)和原乙酸三乙酯(0.6mL)置于微波管中100℃反应10分钟。将反应液冷却至室温后减压浓缩,残留物用无水乙醇(2mL)打浆,过滤,滤饼真空干燥得到7-溴-5-氯-2-甲基-3H-吡啶并[2,1-f][1,2,4]三嗪-4,8-二酮(中间体5.1,50mg)为白色固体。m/z:[M+H]+289.8.
中间体6.1的合成
步骤1:冰浴条件下,将2-甲基-3-硝基-5-溴苯胺(5g,21.6mmol)的乙腈(40mL)溶液滴加到氯化亚铜(3.3g,33.5mmol)和亚硝酸叔丁酯(3.5g,33.5mmol)的乙腈(40mL)混悬液中,反应体系在30℃下搅拌过夜。将反应液倒入盐酸(0.5N)中,用EtOAc(3×150mL)萃取,合并有机相后用无水硫酸钠干燥,过滤、滤液减压浓缩,残留物用Flash柱层析(PE/EtOAc=1/1)纯化得到5-溴-1-氯-2-甲基-3-硝基苯(3.23g)为黄白色固体。1H NMR(400MHz,DMSO-d6):δ8.15(d,J=8.8Hz,2H),2.37(s,3H).
步骤2:80℃下,6小时内往步骤1所得产物(5g,20mmol)的吡啶(75mL)和水(50mL)的混合溶液中分批加入高锰酸钾(15.8g,100mmol),反应体系在80℃下搅拌过夜。向反应液中加入乙醇(100mL),回流30分钟后趁热过滤,滤饼用THF(3×50mL)洗涤。将合并的滤液浓缩,残留物中加入10%氢氧化钠水溶液,用EtOAc(3×80mL)萃取除去杂质。水相用1N盐酸调节pH=2后用DCM/MeOH=10/1(3×80mL)萃取,合并有机相后用无水硫酸钠干燥,过滤、减压浓缩得到4-溴-2-氯-6-硝基苯甲酸(1.56g)为类白色固体。1H NMR(400MHz,DMSO-d6):δ14.55(br.s,1H),8.39(d,J=5.6Hz,2H).
步骤3:往步骤2所得产物(1.96g,7mmol)中依次加入氢氧化钠水溶液(0.88N,9.8mL)、三氯化铁(0.12g,0.77mmol)和异丙醇(1.0mL),将反应体系加热至75℃,搅拌下缓慢向其中滴加80%水合肼(2.2g,35.2mmol),反应体系在75℃下搅拌2小时。冷却至室温后过滤,滤液浓缩后倒入水(10mL)中,用1N盐酸调pH=2,过滤、滤饼真空干燥后得到2-氨基-4-溴-6-氯苯甲酸(中间体6.1,1.5g)为类白色固体。m/z:[M+H]+249.8.
中间体6.2的合成
步骤1:向三氯乙醛(9g,61mmol)、无水硫酸钠(35g,243mmol)和水(165mL)混合物中加入3-溴-5-氯-2-甲氧基苯胺(7.2g,30.4mmol)的DMF(75mL)溶液,随后加入浓盐酸(3.8mL),反应体系在90℃下搅拌25分钟。将盐酸羟胺(12.7g,182mmol)加入上述反应体系中并在90℃下搅拌5小时。将反应混合物冷却至室温,加水(1L)剧烈搅拌,过滤、滤饼真空干燥后得到N-(3-溴-5-氯-2-甲氧基苯基)-2-(肟基)乙酰胺(7.56g)为黄白色固体。m/z:[M+H]+307.0;1H NMR(400MHz,DMSO-d6):δ12.52(s,1H),9.54(s,1H),8.23(s,1H),7.81(s,1H),7.54(s,1H),3.78(s,3H).
步骤2:将浓硫酸(60mL)预热至30℃,搅拌下分批加入步骤1所得产物(7.4g,23.9mmol)并保持内温在30~50℃,加毕,反应体系在70℃下搅拌15分钟。将反应混合物缓慢倒入剧烈搅拌的碎冰(160g)和冰水(320mL)中。过滤收集析出的固体,并用冰水洗涤pH=7后真空干燥,干燥后固体用乙醇(20mL)打浆,过滤、滤饼真空干燥后得到6-溴-4-氯-7-甲氧基吲哚啉-2,3-二酮(5.59g)为橙色固体。m/z:[M+H]+289.8;1H NMR(400MHz,DMSO-d6):δ11.63(s,1H),7.43(s,1H),3.75(s,3H).
步骤3:冰浴条件下,向步骤2所得产物(5.6g,19.2mmol)的1,4-二氧六环溶液(84mL)中加入30%双氧水(9.8mL),然后滴加氢氧化钠水溶液(0.67N,360mL),得到的混合物缓慢升到室温并搅拌3小时。用乙酸乙酯(3×80mL)萃取除去杂质,水相用1N盐酸调节pH=2后,用乙酸乙酯(3×80mL)萃取,合并有机相后用无水硫酸钠干燥,过滤、滤液减压浓缩得到2-氨基-4-溴-6-氯-3-甲氧基苯甲酸(中间体6.2,4.58g)为黄色固体。m/z:[M+H]+279.8.
中间体6.3的合成
利用中间体6.2的合成方法,用3-溴-5-氯-2-氟苯胺(合成方法参考US20110052578A1)反应得到2-氨基-4-溴-6-氯-3-氟苯甲酸(中间体6.3)。m/z:[M+H]+267.8.
中间体6.4的合成
步骤1:将2,3-二甲基-5-溴硝基苯(31.2g,132mmol)溶于DMF(150mL)中,溶液加热至100℃搅拌过夜。待冷至室温,将反应液迅速加入到预先冷却的高碘酸钠(113.2g,529mmol)溶液(DMF/水=1/1,300mL)中。反应液室温搅拌5小时,过滤。滤饼用PE/EtOAc(10/1)洗涤至无产物,滤液用PE/EtOAc(10/1)萃取。合并有机相,无水硫酸钠干燥。过滤,减压浓缩。残留物用Flash柱层析(PE/EtOAc=10/1)纯化得到4-溴-2-甲基-6-硝基苯甲醛(5.8g)为浅褐色固体。1H NMR(400MHz,CDCl3):δ10.28(s,1H),8.11(s,1H),7.75(s,1H),2.50(s,3H).
步骤2:将步骤1所得产物(4.8g,19.7mmol)和氯化铵(10.5g,196.7mmol)的乙醇/水(3/1,200mL)溶液加热至60℃,然后分批加入铁粉(11g,197mmol),得到的混合物搅拌2小时。过滤,滤饼用EtOAc洗涤至无产物残留,滤液用EtOAc萃取。合并有机相,分别用水,饱和食盐水洗涤,无水硫酸钠干燥。过滤,滤液减压浓缩得到2-氨基-4-溴-6-甲基苯甲醛(4.1g)为浅褐色固体。m/z:[M+H]+216.0;1H NMR(400MHz,DMSO-d6):δ10.24(s,1H),7.58(br.s,2H),6.91(s,1H),6.61(s,1H),2.54(s,3H).
步骤3:将亚氯酸钠(5.2g,57.46mmol)和磷酸二氢钠(6.89g,57.5mmol)溶解于水(50mL)中,然后将该溶液滴加到步骤2所得产物(4.1g,19.2mmol)和2-甲基-2-丁烯(6.72g,95.8mmol)的叔丁醇/THF(1/1,100mL)溶液中,室温搅拌过夜。用氢氧化钠水溶液(0.5M)淬灭反应,EtOAc萃取。水相再用稀盐酸(1N)调pH=6,用DCM萃取。合并DCM相,用饱和食盐水洗涤,无水硫酸钠干燥,过滤、滤液减压浓缩。残留物用DCM/PE(1/100)洗涤,过滤,滤饼真空干燥得到2-氨基-4-溴-6-甲基苯甲酸(化合物6.4,2.15g)为浅褐色固体。m/z:[M+H]+230.0.
中间体7.1的合成
向2,6-二氯-4-甲基烟酰胺(2.6g,12.7mmol)和1,4-二氧六环(25mL)的混合物中加入氨水(10mL)。将反应体系密封,加热到135℃搅拌24小时。减压浓缩,残留物经Flash柱层析纯化(DCM/MeOH=50/1~20/1)得到2-氨基-6-氯-4-甲基烟酰胺(中间体7.1,660mg)为浅黄色固体。m/z:[M+H]+186.0;1H NMR(400MHz,DMSO-d6):δ7.80(s,1H),7.64(s,1H),6.50(s,1H),6.17(s,2H),2.20(s,3H).
中间体8.1的合成
步骤1:2-氨基-4-溴-3-甲氧基-6-甲基苯甲酸(合成方法参考US2009143353A1)(2.6g,10mmol)、HOBT(1.6g,12mmol)和EDCI(2.1g,11mmol)溶解于DMF(25mL)中,室温搅拌15分钟,冷却至0℃,滴加30%氨水(25mL),室温搅拌16小时。用乙酸乙酯萃取(50mL×3),合并有机相用饱和食盐水洗涤,无水硫酸钠干燥,过滤、滤液减压浓缩,残留物用EtOAc/PE(9/1)溶液打浆,过滤,滤饼真空干燥得到2-氨基-4-溴-3-甲氧基-6-甲基苯甲酰胺(1.2g)为淡黄色固体。m/z:[M+H]+259.0,1H NMR(400MHz,DMSO-d6):δ7.75(s,1H),7.59(s,1H),6.66(s,1H),4.99(br.s,2H),3.66(s,3H),2.17(s,3H).
步骤2:将步骤1所得产物(200mg,0.77mmol)和环戊酮(324mg,3.86mmol)混悬于乙醇(5mL)中,加入浓硫酸(75mg,0.77mmol),反应液95℃回流3小时,冷却至室温,过滤得到7'-溴-8'-甲氧基-5'-甲基-1'H-螺[环戊烷-1,2'-喹唑啉]-4'(3'H)-酮(中间体8.0,250mg)为灰色固体。m/z:[M+H]+259.0.
步骤3:将中间体8.0(150mg,0.46mmol)和碘甲烷(0.5mL)的DMF(3mL)溶液在封管中105℃搅拌过夜,反应液冷却至室温,加乙酸乙酯稀释,有机相用硫代硫酸钠水溶液洗涤,分离有机相并用无水硫酸钠干燥,过滤、滤液减压浓缩,残留物用Flash柱层析(PE/EtOAc=3/1)纯化得到7'-溴-8'-甲氧基-1',5'-二甲基-1'H-螺[环戊烷-1,2'-喹唑啉]-4'(3'H)-酮(中间体8.1,75mg)为白色固体。m/z:[M+H]+339.0.
中间体8.2-8.16的合成
利用中间体8.0的合成方法,用相应的取代的苯甲酸或苯甲酰胺和相应的环烷基酮或杂环烷基酮反应得到中间体8.2-8.14:
利用中间体8.1的合成方法,用相应的取代的苯甲酸或苯甲酰胺和环丁酮反应得到中间体8.15-8.16:
表5
中间体9.1的合成
步骤1:依次将Xantphos(18mg,30.2μmol)和Pd2(dba)3(14mg,15.2mmol)加入到N,N-二甲基-3-(哌嗪-1-基)丙-1-胺(100mg,0.302mmol)、N,N-二-Boc-2-氨基-6-氯嘧啶(156mg,0.30mmol)和碳酸铯(494mg,1.52mmol)的1,4-二氧六环(10mL)溶液中,反应体系用氮气置换三次后在95℃下搅拌3小时,冷却后加水(15mL)淬灭反应,水相用乙酸乙酯(3×10mL)萃取,合并有机相减压浓缩,残留物用prep-TLC(PE/EtOAc=1/1)纯化得N,N-二-Boc-2-氨基-6-(4-(3-(二甲基氨基)丙基)哌嗪-1-基)嘧啶(80mg)为淡棕色液体。m/z:[M+H]+465.2.
步骤2:将TFA(2mL)加入步骤1所得产物(80mg,0.172mmol)的DCM(5mL)溶液中,反应体系室温搅拌4小时,将反应液浓缩后得6-(4-(3-(二甲基氨基)丙基)哌嗪-1-基)嘧啶-4-胺(中间体9.1,80mg)为黄色油状物。m/z:[M+H]+264.0.
化合物的合成:
实施例1:7'-((6-氨基嘧啶-4-基)氨基)-5'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-1)的合成
步骤1:将中间体1.1(100mg,0.3mmol),6-氨基嘧啶-4-氨基甲酸叔丁酯(77.3mg,0.37mmol),Pd2(dba)3(15mg),Xantphos(15mg),Cs2CO3(200mg,0.61mmol)和1,4-二氧六环(2.5mL)的混合物用氮气置换3次,然后将反应体系升温至85℃搅拌3小时。将反应液减压浓缩,残留物用乙醇(2.5mL)打浆,过滤,滤饼用少量冷乙醇淋洗,滤饼真空干燥后得到(6-((5'-甲基-4',8'-二羰基-1',3',4',8'-四氢螺[环己烷-1,2'-吡啶[2,1-f][1,2,4]三嗪]-7'-基)氨基)嘧啶-4-基)氨基甲酸叔丁酯(200mg,粗品)为黄色固体。m/z:[M+H]+456.0.
步骤2:冰浴条件下,向步骤1所得产物(200mg,粗品)的DCM(1.5mL)溶液中滴加TFA(1.8mL),加毕,将反应体系缓慢升至室温并搅拌1.5小时。将反应液减压浓缩,残留物中加入饱和碳酸氢钠水溶液调节pH=7,有气泡产生并有灰色固体析出,过滤,收集固体并用prep-HPLC(分离条件2)纯化得化合物1-1(27.5mg,两步产率:26%)为淡黄色固体。m/z:[M+H]+356.0;1H NMR(400MHz,DMSO-d6):δ9.81(s,1H),8.98(s,1H),8.47(s,1H),7.98(br.s,3H),6.42(s,1H),2.43(s,3H),1.73-1.20(m,10H).
实施例2:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-2)的合成
将中间体1.1(50mg,0.15mmol),7H-吡咯并[2,3-d]嘧啶-4-胺(25mg,0.18mmol),Pd2(dba)3(10mg),Xantphos(10mg),Cs2CO3(100mg,0.3mmol)和1,4-二氧六环(1.2mL)的混合物用氮气置换3次,然后将反应体系升温至95℃搅拌6小时。将反应液减压浓缩,残留物用prep-HPLC(分离条件2)纯化得到化合物1-2(20mg,产率:34%)为黄色固体。m/z:[M+H]+380.0;1H NMR(400MHz,DMSO-d6):δ12.42(s,1H),9.75(br.s,1H),9.03(s,1H),8.45(s,1H),8.21(s,1H),7.46(s,1H),6.89(s,1H),2.49(s,3H),1.75-1.25(m,10H).
实施例3:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-3)的合成
利用化合物1-2的合成方法,将中间体1.1替换为1.2得到化合物1-3为白色固体。m/z:[M+H]+400.0;1H NMR(400MHz,DMSO-d6):δ12.27(s,1H),9.25(br.s,1H),9.12(s,1H),8.64(s,1H),8.51(s,1H),7.44(s,1H),6.89(s,1H),1.84-1.16(m,10H).
实施例4:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-1',5'-二甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-4)的合成
步骤1:将中间体1.1(50mg,0.15mmol)和碘甲烷(44mg,0.31mmol)加入到DMF(5mL)中,反应体系在封管中加热到70℃搅拌2天。将反应液倒入到EtOAc中,分别用水和饱和食盐水洗涤,分离有机相并用无水硫酸钠干燥、过滤,滤液减压浓缩,残留物用prep-TLC(DCM/MeOH=20/1)纯化得7'-溴-1',5'-二甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮(30mg,产率:58%)为黄色液体。m/z:[M+H]+340.0,342.0.
步骤2:依次将XPhos(4mg,8.82μmol)、Xantphos(5mg,8.82μmol)和Pd2(dba)3(4mg,4.41μmol)加入到步骤1所得产物(30mg,88.2μmol)、7H-吡咯并[2,3-d]嘧啶-4-胺(13mg,97.0μmol)和Cs2CO3(37mg,0.12mmol)的1,4-二氧六环(4mL)溶液中,反应体系用氮气置换三次,然后在110℃微波反应3小时,过滤,滤液减压浓缩,残留物用prep-HPLC(分离条件2)纯化得化合物1-4(11.3mg,产率:33%)为淡黄色固体。m/z:[M+H]+394.0;1H NMR(400MHz,DMSO-d6):δ12.16(br.s,1H),8.74(s,1H),8.46(s,2H),7.42(s,1H),6.79(s,1H),2.58(s,3H),2.50(3H,overlapping with solvent),2.20-1.23(m,10H).
实施例5:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-1'-丙烯酰-5'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-5)的合成
步骤1:将丙烯酰氯(1.2mL,14.8mmol)滴加到中间体1.1(0.30g,0.9mmol)的DMF(9mL)溶液中,反应体系在85℃下搅拌20分钟。冰浴下,将反应液倒入到饱和碳酸氢钠水溶液(30mL)中淬灭反应,水相用EtOAc萃取(3×15mL),合并有机相后用饱和食盐水洗涤、无水硫酸钠干燥,过滤,滤液减压浓缩,残留物用prep-TLC(PE/EtOAc=1/2)纯化得到1'-丙烯酰-7'-溴-5'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮(250mg,产率:71%)为淡黄色固体。m/z:[M+H]+380.0.
步骤2:依次将Ru-phos(6mg,13.2μmol)和Pd2(dba)3(6.0mg,6.6mmol)加入到步骤1所得产物(50mg,0.13mmol)、7H-吡咯并[2,3-d]嘧啶-4-胺(27mg,0.20mmol)和叔丁醇钠(16mg,0.17mmol)的甲苯(3mL)溶液中,反应体系用氮气置换三次后在105℃下搅拌3小时,冷却后加水(15mL)淬灭反应,水相用乙酸乙酯(3×10mL)萃取,合并有机相减压浓缩,残留物用prep-HPLC(分离条件2)纯化得化合物1-5(0.65mg,产率:1%)为淡黄色固体。m/z:[M+H]+434.1;1H NMR(400MHz,DMSO-d6):δ12.06(br.s,1H),9.31(s,1H),8.77(s,1H),8.73(s,1H),8.49(s,1H),7.39(s,1H),6.86(s,1H),6.29-6.21(m,1H),6.10-6.01(m,1H),5.79-5.73(m,1H),3.03-2.97(m,1H),2.50(overlapping with solvent,3H),1.89-1.27(m,9H)。
实施例6:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-1'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-6)的合成
利用化合物1-4的合成方法,将中间体1.1替换为1.2得到化合物1-6为淡黄色固体。m/z:[M+H]+414.0;1H NMR(400MHz,DMSO-d6):δ12.18(s,1H),9.02(s,1H),8.93(s,1H),8.72(s,1H),8.51(s,1H),7.43(s,1H),6.85(s,1H),2.61(s,3H),1.65-1.27(m,10H).
实施例7:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯螺[环戊烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-7)的合成
利用化合物1-2的合成方法,将中间体1.1替换为1.3得到化合物1-7为淡黄色固体。m/z:[M+H]+386.0;1H NMR(400MHz,DMSO-d6):δ12.24(s,1H),9.30(s,1H),9.20(br.s,1H),8.66(s,1H),8.51(s,1H),7.43(s,1H),6.88(s,1H),1.84-1.70(m,8H).
实施例8:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-1'-乙基-5'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-8)的合成
利用化合物1-4的合成方法,将碘甲烷替换为碘乙烷得到化合物1-8为淡黄色固体。m/z:[M+H]+408.0;1H NMR(400MHz,DMSO-d6):δ12.49(br.s,1H),9.83(br.s,1H),8.81(s,1H),8.47(s,1H),8.23(br.s,1H),7.47(s,1H),6.91(s,1H),3.31-3.17(m,1H),2.90-2.78(m,1H),2.48(s,3H),2.00-1.89(m,1H),1.79-1.44(m,6H),1.38-1.20(m,3H),0.97(t,J=7.2Hz,3H).
实施例9:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-9)的合成
利用化合物1-2的合成方法,将中间体1.1替换为1.4得到化合物1-9为淡黄色固体。m/z:[M+H]+372.0;1H NMR(400MHz,DMSO-d6):δ12.28(s,1H),9.58(s,1H),9.31(br.s,1H),8.62(s,1H),8.51(s,1H),7.45(s,1H),6.90(s,1H),2.24-2.16(m,4H),1.90-1.75(m,2H).
实施例10:7-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5-氯-2,2-二甲基-2,3-二氢-1H-吡啶并[2,1-f][1,2,4]三嗪-4,8-二酮盐酸盐(化合物1-10)的合成
利用化合物1-2的合成方法,将中间体1.1替换为1.5得到化合物1-10为白色固体。m/z:[M+H]+360.0;1H NMR(400MHz,DMSO-d6):δ12.29(br.s,1H),9.40(br.s,1H),9.17(s,1H),8.64(s,1H),8.51(s,1H),7.44(s,1H),6.90(s,1H),1.36(s,6H).
实施例11:7'-((6-氨基-5-氟嘧啶-4-基)氨基)-5'-氯螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-11)的合成
利用化合物1-1的合成方法,用中间体1.4和(6-氨基-5-氟嘧啶-4-基)氨基甲酸叔丁酯反应得到化合物1-11为淡黄色固体。m/z:[M+H]+366.0;1H NMR(400MHz,DMSO-d6):δ9.51(s,1H),8.42(s,1H),8.20(s,1H),8.09(s,1H),7.35-7.05(m,3H),2.25-2.10(m,3H),2.05-1.95(m,1H),1.88-1.70(m,2H).
实施例12:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-1'-甲基螺[环戊烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-12)的合成
利用化合物1-4的合成方法,将中间体1.1替换为1.3得到化合物1-12为淡黄色固体。m/z:[M+H]+400.0;1H NMR(400MHz,DMSO-d6):δ12.37(br.s,1H),9.58(br.s,1H),9.25(s,1H),8.64-8.45(m,2H),7.46(s,1H),6.92(s,1H),2.66(s,3H),2.01-1.55(m,8H).
实施例13:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-1'-异丙基-5'-甲基螺[环己烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-13)的合成
依次将XPhos(6mg,13.6μmol)、Xantphos(8mg,13.6μmol)和Pd2(dba)3(6mg,6.80μmol)加入到中间体1.8(50mg,136μmol)、7H-吡咯并[2,3-d]嘧啶-4-胺(22mg,163μmol)和Cs2CO3(66mg,0.20mmol)的1,4-二氧六环(10mL)溶液中,反应体系用氮气置换三次,然后在95℃下搅拌16小时,过滤,滤液浓缩后用prep-HPLC(分离条件2)纯化得化合物1-13(19.8mg,产率:29%)为淡黄色固体。m/z:[M+H]+422.0;1H NMR(400MHz,DMSO-d6):δ12.42(br.s,1H),9.45(br.s,1H),8.80(s,1H),8.47(s,1H),8.45(s,1H),7.44(t,J=2.8Hz,1H),6.88(t,J=2.4Hz,1H),2.47(overlapping with solvent,3H),2.05-1.85(m,1H),1.60-1.84(m,4H),1.45-1.55(m,2H),1.44-1.20(m,4H),1.18(d,J=6.4Hz,3H),0.90(d,J=6.4Hz,3H)。
实施例14:N-(5-氯-6-((5'-氯-4',8'-二氧代-1',3',4',8'-四氢螺[环戊烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-7'-基)氨基)嘧啶-4-基)环丙酰胺盐酸盐(化合物1-14)的合成
利用化合物1-2的合成方法,用中间体1.3和N-(6-氨基-5-氯嘧啶-4-基)环丙酰胺反应得到化合物1-14为淡黄色固体。m/z:[M+H]+464.0;1H NMR(400MHz,DMSO-d6):δ10.77(s,1H),9.33(s,1H),8.90(s,1H),8.69(s,1H),8.58(s,1H),7.06(br.s,1H),2.05-1.85(m,1H),1.84-1.60(m,8H),0.90-0.80(m,4H).
实施例15:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-15)的合成
利用化合物1-2的合成方法,将中间体1.1替换为1.6得到化合物1-15为黄色固体。m/z:[M+H]+352.0;1H NMR(400MHz,DMSO-d6):δ12.75(br.s,1H),10.87(br.s,1H),9.60(s,1H),8.44(s,1H),7.90(br.s,1H),7.52(s,1H),7.05(s,1H),2.44(s,3H),2.30-2.18(m,4H),1.85-1.74(m,2H).
实施例16:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-1'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-16)的合成
利用化合物1-4的合成方法,将中间体1.1替换为1.4得到化合物1-16为黄色固体。m/z:[M+H]+386.0;1H NMR(400MHz,DMSO-d6):δ12.27(s,1H),9.46(s,1H),9.32(s,1H),8.64(s,1H),8.51(s,1H),7.45(s,1H),6.90(s,1H),2.60(s,3H),2.32(dd,J=15.0,7.6Hz,2H),2.05-1.92(m,2H),1.81(dd,J=15.2,7.6Hz,2H).
实施例17:7'-((6-氨基-5-氯嘧啶-4-基)氨基)-5'-氯螺[环戊烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-17)的合成
将氢氧化钾(145mg,2.58mmol)加入到化合物1-14(120mg,0.26mmol)的乙醇(5mL),THF(5mL)和水(5mL)的混合溶液中,将反应体系加热到50℃搅拌16小时。将反应液减压浓缩,残留物用水打浆、过滤,得到固体用prep-HPLC(分离条件2)纯化得化合物1-17(7.8mg,产率:8%)为淡黄色固体。m/z:[M+H]+396.0;1H NMR(400MHz,DMSO-d6):δ9.26(s,1H),8.54(s,2H),8.23(s,1H),7.25(br.s,2H),1.81-1.23(m,6H).
实施例18:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-1',5'-二甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-18)的合成
利用化合物1-4的合成方法,将中间体1.1替换为1.6得到化合物1-18为黄色固体。m/z:[M+H]+366.0;1H NMR(400MHz,DMSO-d6):δ12.59(s,1H),10.32(s,1H),9.37(s,1H),8.44(s,1H),8.08(s,1H),7.49(s,1H),6.98(s,1H),2.57(s,3H),2.45(s,3H),2.38-2.29(m,2H),2.02-1.91(m,2H),1.82-1.75(m,2H).
实施例19:N-(3-(7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-甲基-4',8'-二氧代-3',4'-二氢螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-1'(8'H)-基)苯基)丙烯酰胺盐酸盐(化合物1-19)的合成
步骤1:将铁粉(75mg,1.33mmol)加入到化合物Z-1(利用化合物2的合成方法,将中间体1.1替换为1.9得到化合物Z-1)(90mg,0.19mmol)的醋酸溶液(5mL)中,反应体系在50℃下搅拌16小时。冷却后过滤,滤液浓缩后倒入水中,用饱和碳酸氢钠水溶液调pH=7,过滤、滤饼真空干燥后得到化合物Z-2(80mg,产率:95%)为黄色固体。m/z:[M+H]+443.0.
步骤2:0℃下将丙烯酰氯(15mg,170μmol)滴加到化合物Z-2(50mg,113μmol)的DMF(2mL)溶液中,反应体系在室温下搅拌20分钟。0℃下将反应液倒入到饱和碳酸氢钠水溶液(15mL)中淬灭反应,水相用乙酸乙酯萃取(3×15mL),合并有机相并减压浓缩,残留物用prep-HPLC(分离条件2)纯化得化合物1-19(0.62mg,产率:1%)为淡黄色固体。m/z:[M+H]+497.0;1H NMR(400MHz,DMSO-d6):δ12.15(br.s,1H),10.24(s,1H),9.53(s,1H),9.02(br.s,1H),8.59(s,1H),8.47(s,1H),7.50-7.44(m,1H),7.39(s,2H),7.29-7.21(m,1H),6.80(s,1H),6.64-6.56(m,1H),6.45-6.34(m,1H),6.28-6.18(m,1H),5.77-5.68(m,1H),2.89-2.79(m,1H),2.54(s,3H),2.39-2.14(m,2H),2.05-1.85(m,3H).
实施例20:5'-氯-1'-甲基-7'-(噻吩并[2,3-d]嘧啶-4-基氨基)螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-20)的合成
利用化合物1-4的合成方法,用中间体1.4和噻吩并[2,3-d]嘧啶-4-胺反应得到化合物1-20为黄色固体。m/z:[M+H]+403.0;1H NMR(400MHz,DMSO-d6):δ9.47(s,1H),9.27(s,1H),8.76(s,1H),8.72(s,1H),7.90-7.82(m,2H),2.61(s,3H),2.50-2.33(m,2H),2.00-1.95(m,2H),1.85-1.75(m,2H).
实施例21:5'-氯-7'-(噻吩并[2,3-d]嘧啶-4-基氨基)螺[环戊烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-21)的合成
利用化合物1-2的合成方法,用中间体1.3和噻吩并[2,3-d]嘧啶-4-胺反应得到化合物1-21为淡黄色固体。m/z:[M+H]+403.0;1H NMR(400MHz,DMSO-d6):δ9.32(s,1H),9.24(s,1H),8.76(s,1H),8.70(s,1H),7.90-7.83(m,2H),7.55-7.33(m,1H),1.90-1.79(m,2H),1.78-1.64(m,6H).
实施例22:7'-((1H-吡唑并[3,4-d]嘧啶-4-基)氨基)-5'-氯-1'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-22)的合成
利用化合物1-4的合成方法,用中间体1.4和1H-吡唑并[3,4-d]嘧啶-4-胺反应得到化合物1-22为淡黄色固体。m/z:[M+H]+387.2;1H NMR(400MHz,DMSO-d6):δ13.83(br.s,1H),9.77(s,1H),9.46(s,1H),8.83(s,1H),8.63(s,1H),8.62(s,1H),2.61(s,3H),2.45-2.23(m,2H),2.03-1.92(m,2H),1.86-1.75(m,2H).
实施例23:7'-((6-氨基嘧啶-4-基)氨基)-5'-氯-1'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-23)的合成
步骤1:氮气保护下,将中间体2.1(40mg,0.15mmol),N,N-二-Boc-2-氨基-6-氯嘧啶(59mg,0.18mmol),Pd2(dba)3(5mg),Xantphos(5mg),XPhos(5mg),Cs2CO3(73mg,0.22mmol)和叔丁醇(1.5mL)的混合物在85℃下搅拌8小时。将反应液减压浓缩,残留物用prep-TLC(PE/EtOAc=1/1)纯化得到化合物X-1(60mg,产率:73%)为淡黄色固体。m/z:[M+H]+562.0.
步骤2:冰浴条件下,向化合物X-1(60mg,0.11mmol)的DCM(0.4mL)溶液中滴加TFA(0.4mL),加毕,反应液室温搅拌12小时。将反应液减压浓缩,残留物用DCM稀释,加入碳酸氢钠固体调节pH=7,搅拌约20分钟,过滤,滤液减压浓缩,残留物用prep-HPLC(分离条件2)纯化得到化合物1-23(1.67mg,产率:4%)为黄色固体。m/z:[M+H]+362.2;1H NMR(400MHz,DMSO-d6):δ9.97(s,1H),9.45(s,1H),8.53(s,1H),8.32(s,1H),7.98(s,2H),6.56(s,1H),2.56(s,3H),2.40-2.27(m,2H),2.00-1.90(m,2H),1.84-1.76(m,2H).
实施例24:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-3,3-二甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-24)的合成
利用化合物1-2的合成方法,用将中间体1.1替换为1.10得到化合物1-24为淡黄色固体。m/z:[M+H]+400.2;1H NMR(400MHz,DMSO-d6):δ12.18(s,1H),9.48(s,1H),9.08(br.s,1H),8.73(s,1H),8.51(s,1H),7.42(s,1H),6.92(s,1H),2.04(s,4H),1.28(s,3H),1.15(s,3H).
实施例25:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-1',3,3-三甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-25)的合成
利用化合物1-4的合成方法,用将中间体1.1替换为1.10得到化合物1-25为淡黄色固体。m/z:[M+H]+414.2;1H NMR(400MHz,DMSO-d6):δ12.24(s,1H),9.39(s,1H),9.23(br.s,1H),8.69(s,1H),8.51(s,1H),7.44(s,1H),6.92(s,1H),2.59(s,3H),2.26-2.13(m,2H),1.91-1.76(m,2H),1.22(s,3H),1.15(s,3H).
实施例26:7-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5-氯-2-(3-氟苯基)-2-甲基-2,3-二氢-1H-吡啶并[2,1-f][1,2,4]三嗪]-4,8-二酮盐酸盐(化合物1-26)的合成
利用化合物1-2的合成方法,用将中间体1.1替换为1.11得到化合物1-26为淡黄色固体。m/z:[M+H]+440.2;1H NMR(400MHz,DMSO-d6):δ12.28(s,1H),9.95(s,1H),9.32(br.s,1H),8.55-8.40(m,2H),7.81(br.s,1H),7.45-7.30(m,4H),7.09(t,J=8.4Hz,1H),6.92(s,1H),1.65(s,3H).
实施例27:7'-((6-氨基-5-氟嘧啶-4-基)氨基)-5'-氯螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-27)的合成
利用化合物1-1的合成方法,用化合物1.4和(6-氨基-5-氯嘧啶-4-基)氨基甲酸叔丁酯反应得到化合物1-27为淡黄色固体。m/z:[M+H]+382.1;1H NMR(400MHz,DMSO-d6):δ9.54(s,1H),8.56(s,1H),8.53(s,1H),8.25(s,1H),7.36(br.s,2H),2.17(t,J=8.0Hz,4H),1.86-1.72(m,2H).
实施例28:8-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-6-氯-3a-甲基-2,3,3a,4-四氢-1H-吡啶并[2,1-f]吡咯并[1,2-b][1,2,4]三嗪-5,9-二酮盐酸盐(化合物1-28)的合成和实施例29:7-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-9-氯-3a-甲基-2,3,3a,4-四氢-1H-吡啶并[2,1-f]吡咯并[2,1-c][1,2,4]三嗪-6,10-二酮盐酸盐(化合物1-29)的合成
利用化合物1-2的合成方法,用将中间体1.1替换为3.1和3.2的混合物得到化合物1-28和1-29均为淡黄色固体(prep-HPLC分离条件:3)。化合物1-28,UPLC RT=4.508min,m/z:[M+H]+386.2;1H NMR(400MHz,DMSO-d6):δ12.24(s,1H),9.20(br.s,1H),8.95(s,1H),8.68(s,1H),8.51(s,1H),7.44(s,1H),6.88(s,1H),3.71-3.62(m,2H),2.00-1.86(m,4H),1.31(s,3H);化合物1-29,UPLC RT=4.550min,m/z:[M+H]+386.2;1H NMR(400MHz,DMSO-d6):δ12.20(s,1H),9.09(br.s,1H),8.72(s,1H),8.51(s,1H),7.42(s,1H),6.89(s,1H),3.63-3.53(m,2H),2.09-1.90(m,4H),1.26(s,3H).
实施例30:8-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-3a,6-二甲基-2,3,3a,4-四氢-1H-吡啶并[2,1-f]吡咯并[1,2-b][1,2,4]三嗪-1,5,9-三酮(化合物1-30)的合成
利用化合物1-2的合成方法,用将中间体1.1替换为4.1得到化合物1-30为淡黄色固体(prep-HPLC分离条件:1)。m/z:[M+H]+380.1;1H NMR(400MHz,DMSO-d6):δ12.05(s,1H),9.11(s,1H),8.78(s,1H),8.66(s,1H),8.48(s,1H),7.38(s,1H),6.85(s,1H),2.78-2.64(m,2H),2.50(overlapping,3H),2.40-2.26(m,2H),1.49(s,3H).
实施例31:7'-((6-氨基-5-(1-甲基-1H-吡唑-4-基)嘧啶-4-基)氨基)-5'-氯螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-31)的合成
利用化合物1-1的合成方法,用中间体1.4和(6-氨基-5-(1-甲基-1H-吡唑-4-基)嘧啶-4-基)氨基甲酸叔丁酯反应得到化合物1-31为淡黄色固体。m/z:[M+H]+428.2;1H NMR(400MHz,DMSO-d6):δ12.09(s,1H),9.58(s,1H),8.61(s,1H),8.44(d,J=8.0Hz,2H),8.01(s,1H),7.64(br.s,3H),3.96(s,3H),2.22-2.00(m,4H),1.87-1.67(m,2H).
实施例32:7'-((6-氨基-5-甲氧基嘧啶-4-基)氨基)-5'-氯螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-32)的合成
利用化合物1-1的合成方法,用中间体1.4和(6-氨基-5-甲氧基嘧啶-4-基)氨基甲酸叔丁酯反应得到化合物1-32为淡黄色固体。m/z:[M+H]+378.2;1H NMR(400MHz,DMSO-d6):δ9.56(s,1H),8.57(s,1H),8.37(s,1H),8.29(s,1H),7.70(br.s,2H),3.75(s,3H),2.54(s,1H),2.25-2.08(m,4H),1.92-1.63(m,2H).
实施例33:5'-氯-1'-(2H3)甲基-7'-[(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]-1'H,3'H-螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'-二酮盐酸盐(化合物1-33)的合成
利用化合物1-4的合成方法,用中间体1.4和氘代碘甲烷为起始原料反应得到化合物1-33为黄色固体。m/z:[M+H]+389.0;1H NMR(400MHz,DMSO-d6):δ12.29(s,1H),9.61-9.13(m,2H),8.64(s,1H),8.51(s,1H),7.45(s,1H),6.91(s,1H),2.41-2.26(m,2H),2.09-1.91(m,2H),1.87-1.72(m,2H).
实施例34:5”-氯-7”-[(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]-1”H,3”H-二螺[环丁烷-1,1'-环丁烷-3',2”-吡啶并[2,1-f][1,2,4]三嗪]-4”,8”-二酮盐酸盐(化合物1-34)的合成
利用化合物1-2的合成方法,用将中间体1.1替换为1.13得到化合物1-34为淡黄色固体。m/z:[M+H]+412.2;1H NMR(400MHz,DMSO-d6):δ12.15(s,1H),9.44(s,1H),8.99(br.s,1H),8.76(s,1H),8.51(s,1H),7.42(s,1H),6.90(s,1H),2.27(d,J=12Hz,2H),2.20(d,J=12.4Hz,2H),2.12(t,J=7.2Hz,2H),1.98(t,J=7.2Hz,2H),1.82-1.72(m,2H).
实施例35:5”-氯-1”-甲基-7”-[(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]-1”H,3”H-二螺[环丁烷-1,1'-环丁烷-3',2”-吡啶并[2,1-f][1,2,4]三嗪]-4”,8”-二酮盐酸盐(化合物1-35)的合成
利用化合物1-4的合成方法,将中间体1.1替换为1.13得到化合物1-35为淡黄色固体。m/z:[M+H]+426.2;1H NMR(400MHz,DMSO-d6):δ12.38(s,1H),9.61(br.s,1H),9.41(s,1H),8.55(s,1H),8.52(s,1H),7.46(s,1H),6.95(s,1H),2.57(s,3H),2.44-2.30(m,2H),2.15-1.90(m,6H),1.82-1.70(m,2H).
实施例36:7'-((9H-嘌呤-6-基)氨基)-5'-氯螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-36)的合成
利用化合物1-2的合成方法,用中间体1.4和9H-嘌呤-6-胺反应得到化合物1-36为淡黄色固体。m/z:[M+H]+373.0;1H NMR(400MHz,DMSO-d6):δ9.59(s,1H),9.14(s,1H),8.78(s,1H),8.69(s,1H),8.56(s,1H),2.32-2.09(m,4H),1.93-1.66(m,2H).
实施例37:5'-氯-1'-(2H3)甲基-7'-[(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]-1'H,3'H-螺[环戊烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'-二酮盐酸盐(化合物1-37)的合成
利用化合物1-4的合成方法,用中间体1.3和氘代碘甲烷为起始原料反应得到化合物1-37为黄色固体。m/z:[M+H]+403.0;1H NMR(400MHz,DMSO-d6):δ12.41(br.s,1H),9.70(br.s,1H),9.26(s,1H),8.61-8.41(m,2H),7.46(s,1H),6.93(s,1H),2.03-1.52(m,8H).
实施例38:9-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-7-氯-4a-甲基-1,2,3,4,4a,5-六氢二吡啶并[1,2-b:2',1'-f][1,2,4]三嗪-6,10-二酮盐酸盐(化合物1-38)的合成
利用化合物1-2的合成方法,将中间体1.1替换为3.3得到化合物1-38为黄色固体。m/z:[M+H]+400.0;1H NMR(400MHz,DMSO-d6):δ12.18(s,1H),9.11-8.87(m,2H),8.75(s,1H),8.52(s,1H),7.43(t,J=2.8Hz,1H),6.83(t,J=2.8Hz,1H),3.05(d,J=10.4Hz,1H)2.73-2.61(m,1H),1.94(d,J=13.6Hz,1H),1.80-1.46(m,5H),1.22(s,3H).
实施例39:5'-氯-7'-(嘧啶-4-基氨基)螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-39)的合成
利用化合物1-2的合成方法,用中间体1.4和嘧啶-4-胺反应得到化合物1-39为黄色固体。m/z:[M+H]+333.0;1H NMR(400MHz,DMSO-d6):δ10.40(brs,1H),9.63(s,1H),9.04(s,1H),8.64(s,1H),8.53(d,J=6.4Hz,1H),7.58(d,J=6.4Hz,1H),2.19(t,J=8.0Hz,3H),2.06-1.92(m,1H),1.90-1.72(m,2H).
实施例40:5'-氯-7'-(7H-吡咯并[2,3-d]嘧啶-7-基)螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-40)的合成
利用化合物1-2的合成方法,用中间体1.4和7H-吡咯并[2,3-d]嘧啶反应得到化合物1-40为黄色固体。m/z:[M+H]+357.0;1H NMR(400MHz,DMSO-d6):δ9.95(s,1H),9.44(s,1H),9.19(s,1H),8.28-8.18(m,2H),7.10(d,J=3.6Hz,1H),2.26(t,J=8.0Hz,4H),1.91-1.67(m,2H).
实施例41:8-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-3a,6-二甲基-2,3,3a,4-四氢-1H-吡啶并[2,1-f]吡咯并[1,2-b][1,2,4]三嗪-5,9-二酮盐酸盐(化合物1-41)的合成
利用化合物1-2的合成方法,将中间体1.1替换为3.4得到化合物1-41为淡黄色固体。m/z:[M+H]+366.0;1H NMR(400MHz,DMSO-d6):δ12.54(s,1H),10.12(br.s,1H),8.85(s,1H),8.45(s,1H),8.14(s,1H),7.48(s,1H),6.94(s,1H),3.64(overlapping with thesolvent,1H),2.80-2.70(m,1H),2.50(overlapping with the solvent,3H),2.26-2.11(m,1H),1.93(br.s,3H),1.29(s,3H).
实施例42:7-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5-氯-2-环丁基-2-甲基-2,3-二氢-1H-吡啶并[2,1-f][1,2,4]三嗪]-4,8-二酮盐酸盐(化合物1-42)的合成
利用化合物1-2的合成方法,将中间体1.1替换为1.12得到化合物1-42为淡黄色固体。m/z:[M+H]+400.0;1H NMR(400MHz,DMSO-d6):δ12.12(s,1H),9.12(s,1H),8.85(s,1H),8.75(s,1H),8.50(s,1H),7.40(s,2H),6.85(s,1H),2.54(s,3H),1.88-1.54(m,8H).
实施例43:7-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5-氯-2-甲基-3H-吡啶并[2,1-f][1,2,4]三嗪]-4,8-二酮盐酸盐(化合物1-43)的合成
利用化合物1-2的合成方法,将中间体1.1替换为5.1得到化合物1-43为淡黄色固体。m/z:[M+H]+344.0;1H NMR(400MHz,DMSO-d6+CD3OD):δ8.97(s,1H),8.50(s,1H),7.39(s,1H),6.80(s,1H),2.17(s,3H).
实施例44:7'-((4-氨基-1,3,5-三嗪-2-基)氨基)-5'-氯螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-44)的合成
利用化合物1-2的合成方法,用中间体1.4和2,4-二氨基-1,3,5-三嗪反应得到化合物1-44为淡黄色固体。m/z:[M+H]+349.0;1H NMR(400MHz,DMSO-d6):δ9.57(br.s,1H),8.68-8.47(m,2H),8.44(s,1H),8.39(s,1H),8.07(br.s,1H),7.95(br.s,1H),7.84(s,1H),2.18(t,J=8.4Hz,4H),1.89-1.69(m,2H).
实施例45:9-((6-氨基嘧啶-4-基)氨基)-7-氯-4a-甲基-1,2,3,4,4a,5-六氢二吡啶并[1,2-b:2',1'-f][1,2,4]三嗪-6,10-二酮盐酸盐(化合物1-45)的合成
利用化合物1-1的合成方法,将中间体1.1替换为3.3得到化合物1-45为黄色固体。m/z:[M+H]+376.0,1H NMR(400MHz,DMSO-d6)δ9.98(s,1H),9.06(s,1H),8.56(s,1H),8.32(s,2H),8.09(br.s,2H),6.58(s,1H),3.01(d,J=10.0Hz,1H),2.64(t,J=11.2Hz,1H),1.93(d,J=14.0Hz,1H),1.77-1.44(m,5H),1.19(s,3H).
实施例46:5”-氯-7”-[(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]-1”H,3”H-二螺[环丙烷-1,1'-环丁烷-3',2”-吡啶并[2,1-f][1,2,4]三嗪]-4”,8”-二酮盐酸盐(化合物1-46)的合成
利用化合物1-2的合成方法,用将中间体1.1替换为1.14得到化合物1-46为淡黄色固体。m/z:[M+H]+398.0;1H NMR(400MHz,DMSO-d6):δ12.14(s,1H),9.67(s,1H),8.97(s,1H),8.78(s,1H),8.50(s,1H),7.42(s,1H),6.89(s,1H),2.47-2.23(m,4H),0.58-0.44(m,4H).
实施例47:8-((6-氨基嘧啶-4-基)氨基)-6-氯-3a-甲基-2,3,3a,4-四氢-1H-吡啶并[2,1-f]吡咯烷[1,2-b][1,2,4]三嗪-5,9-二酮盐酸盐(化合物1-47)的合成
利用化合物1-1的合成方法,将中间体1.1替换为3.2得到化合物1-47为黄色固体。m/z:[M+H]+362.0;1H NMR(400MHz,DMSO-d6):δ10.00(s,1H),8.96(s,1H),8.55(s,1H),8.33(s,1H),8.03(s,2H),6.58(s,1H),1.93(s,4H),1.28(s,2H).
实施例48:8-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-6-甲基-3a-苯基-2,3,3a,4-四氢-1H-吡啶并[2,1-f]吡咯烷[1,2-b][1,2,4]三嗪-5,9-二酮盐酸盐(化合物1-48)的合成
利用化合物1-2的合成方法,用将中间体1.1替换为3.6得到化合物1-48为淡黄色固体。m/z:[M+H]+428.0;1H NMR(400MHz,DMSO-d6):δ12.51(br.s,1H),9.99(s,1H),9.68(s,1H),8.41(s,1H),8.05(br.s,1H),7.49(t,J=8.0Hz,3H),7.32(t,J=7.6Hz,2H),7.24(t,J=7.2Hz,1H),6.93(s,1H),3.89(d,J=7.6Hz,1H),2.99(q,J=8.4Hz,1H),2.37(s,4H),2.15-2.04(m,2H),2.02-1.90(m,1H).
实施例49:9-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-4a,7-二甲基-1,2,3,4,4a,5-六氢二吡啶并[1,2-b:2',1'-f][1,2,4]三嗪-6,10-二酮盐酸盐(化合物1-49)的合成
利用化合物1-2的合成方法,用将中间体1.1替换为3.5得到化合物1-49为淡黄色固体。m/z:[M+H]+380.0;1H NMR(400MHz,DMSO-d6):δ12.61(br.s,1H),10.31(br.s,1H),8.96(s,1H),8.44(d,J=1.6Hz,1H),8.07(s,1H),7.50(q,J=2.4Hz,1H),6.95(s,1H),3.08(d,J=10.8Hz,1H),2.64(t,J=10.8Hz,1H),2.49(s,3H),1.94(d,J=13.6Hz,1H),1.77-1.50(m,5H),1.19(s,3H).
实施例50:7'-(4-氨基-7H-吡咯并[2,3-d]嘧啶-7-基)-5'-氯-1'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-50)的合成
N,N-二甲基-N'-(7H-吡咯并[2,3-d]嘧啶-4-基)甲脒的合成:向4-氨基-7H-吡咯[2,3-d]嘧啶(1g,7.45mmol)的DMF(10mL)溶液中加入N,N-二甲基甲酰胺二甲基缩醛(1.07g,8.95mmol),反应体系在室温下搅拌过夜。反应混合物减压浓缩,加入DCM(30mL),用饱和食盐水洗涤、无水硫酸钠干燥,过滤、滤液减压浓缩。残留物用异丙醚打浆、过滤,滤饼干燥得到产物(0.57g)为黄色固体。m/z:[M+H]+190.0;1H NMR(400MHz,DMSO-d6):δ11.64(br.s,1H),8.79(s,1H),8.29(s,1H),7.22(d,J=1.6Hz,1H),6.45(d,J=1.6Hz,1H),3.16(s,3H),3.10(s,3H).
步骤1:氮气保护下,向7'-溴-5'-氯-1'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮(100mg,301μmol)和N,N-二甲基-N'-(7H-吡咯并[2,3-d]嘧啶-4-基)甲脒(74mg,391μmol)的1,4-二氧六环(5mL)溶液中依次加入反式-1,2-环己二胺(17mg,150μmol)、碘化亚铜(27mg,150μmol)和磷酸钾(192mg,902μmol),反应体系用氮气置换三次后在90℃下搅拌过夜。反应冷却后减压浓缩,加水(15mL),用乙酸乙酯(3×15mL)萃取,合并有机相后用饱和食盐水洗涤、用无水硫酸钠干燥,过滤、滤液减压浓缩得到化合物Y-1(125mg,产率98%)为黄色固体。m/z:[M+H]+441.0.
步骤2:向化合物Y-1(125mg,284μmol)的乙醇(3mL)溶液中加入乙二胺(34mg,567μmol),反应体系在80℃下搅拌过夜。反应液减压浓缩,残留物用prep-HPLC(分离条件5)纯化得化合物1-50(49.2mg,产率:45%)为淡黄色固体。m/z:[M+H]+386.0;1H NMR(400MHz,DMSO-d6):δ9.77(s,1H),9.25(br.s,1H),8.55(br.s,1H),8.42(s,1H),8.08(s,1H),7.80-7.74(m,1H),7.10-7.04(m,1H),2.60(s,3H),2.40-2.27(m,2H),2.11-1.96(m,2H),1.88-1.74(m,2H).
实施例51:5'-氯-7'-((6-(4-(3-(二甲基氨基)丙基)哌嗪-1-基)嘧啶-4-基)氨基)-1'-甲基螺[环丁烷-1,2'-吡啶并[2,1-f][1,2,4]三嗪]-4',8'(1'H,3'H)-二酮盐酸盐(化合物1-51)的合成
利用化合物1-4的合成方法,将步骤1中的中间体1.1替换为1.4,步骤2中的7H-吡咯并[2,3-d]嘧啶-4-胺替换为中间体9.1反应得到化合物1-51为黄色固体。m/z:[M+H]+516.0;1H NMR(400MHz,DMSO-d6):δ11.59(br.s,1H),10.76(br.s,1H),9.39(s,1H),9.18(s,1H),8.56(s,1H),8.47(s,1H),6.89(s,1H),4.37(d,J=13.6Hz,2H),3.61(d,J=13.6Hz,2H),3.49(t,J=13.2Hz,2H),3.28-3.14(m,4H),3.08(d,J=10.8Hz,2H),2.76(d,J=4.8Hz,6H),2.56(s,3H),2.40-2.28(m,2H),2.25-2.13(m,2H),2.02-1.88(m,2H),1.86-1.72(m,2H).
实施例52:化合物1-28A和1-28B的制备
将1g的化合物1-28通过SFC手性拆分得到化合物1-28A(430mg,手性分析RT=1.9分钟,e.e%=99.1%)和化合物1-28B(444mg,手性分析RT=2.5分钟,e.e%=98.2%),均为黄色固体。
将化合物1-28A(430mg)加入至DCM(50mL)和MeOH(5mL)的混合物溶液中,然后再加入盐酸甲醇溶液(4N,0.3mL),得到的混合物室温搅拌1小时后直接减压浓缩得到1-28A盐酸盐(428mg)为黄色固体。m/z:[M+H]+428.0;1H NMR(400MHz,DMSO-d6):δ12.24(s,1H),9.20(br.s,1H),8.95(s,1H),8.68(s,1H),8.51(s,1H),7.44(s,1H),6.88(s,1H),3.71-3.62(m,2H),2.00-1.86(m,4H),1.31(s,3H).
利用1-28A的盐酸盐的制备方法,用1-28B制备得到1-28B盐酸盐。m/z:[M+H]+428.0;1H NMR(400MHz,DMSO-d6):δ12.24(s,1H),9.20(br.s,1H),8.95(s,1H),8.68(s,1H),8.51(s,1H),7.44(s,1H),6.88(s,1H),3.71-3.62(m,2H),2.00-1.86(m,4H),1.31(s,3H).
实施例53:化合物1-38A和1-38B的制备
将640mg的化合物1-38通过SFC手性拆分得到化合物1-38A(245mg,手性分析RT=1.96分钟,e.e%=100%)和化合物1-38B(244mg,手性分析RT=2.92分钟,e.e%=99.3%),均为黄色固体。
利用1-28A的盐酸盐的制备方法,用1-38A制备得到1-38A盐酸盐。m/z:[M+H]+400.0,1H NMR(400MHz,DMSO-d6):δ12.18(s,1H),9.11-8.87(m,2H),8.75(s,1H),8.52(s,1H),7.43(t,J=2.8Hz,1H),6.83(t,J=2.8Hz,1H),3.05(d,J=10.4Hz,1H)2.73-2.61(m,1H),1.94(d,J=13.6Hz,1H),1.80-1.46(m,5H),1.22(s,3H).
利用1-28A的盐酸盐的制备方法,用1-38B制备得到1-38B盐酸盐。m/z:[M+H]+400.0,1H NMR(400MHz,DMSO-d6):δ12.18(s,1H),9.11-8.87(m,2H),8.75(s,1H),8.52(s,1H),7.43(t,J=2.8Hz,1H),6.83(t,J=2.8Hz,1H),3.05(d,J=10.4Hz,1H)2.73-2.61(m,1H),1.94(d,J=13.6Hz,1H),1.80-1.46(m,5H),1.22(s,3H).
实施例54:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-8'-甲氧基-5'-甲基-1'H-螺[环戊烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-1)的合成
将中间体8.7(80mg,0.25mmol),7H-吡咯并[2,3-d]嘧啶-4-胺(41mg,0.30mmol),Pd2(dba)3(20mg),Pd(OAc)3(10mg),Xantphos(20mg),Xphos(20mg),Cs2CO3(165mg,0.51mmol)和1,4-二氧六环(3mL)的混合物置于微波反应管中,鼓吹氮气5分钟,然后微波条件下120℃搅拌8小时。将反应液减压浓缩,残留物用prep-HPLC(分离条件4)纯化,得到化合物2-1(7mg,产率:8%)为黄色固体。m/z:[M+H]+380.0;1H NMR(400MHz,DMSO-d6):δ12.42(s,1H),9.75(br.s,1H),9.03(s,1H),8.45(s,1H),8.21(s,1H),7.46(s,1H),6.89(s,1H),2.49(s,3H),1.75-1.25(m,10H).
实施例55:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-1'H-螺[环丁烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-2)的合成
利用化合物2-1的合成方法,将中间体8.7替换为8.8得到化合物2-2为黄色固体。m/z:[M+H]+355.0;1H NMR(400MHz,DMSO-d6):δ12.08(br.s,1H),9.72(br.s,1H),8.53-8.36(m,2H),7.64-7.30(m,3H),7.17(s,1H),6.92-6.85(m,1H),2.32-2.16(m,4H),1.81-1.69(m,2H).
实施例56:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-1'H-螺[环己烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-3)的合成
利用化合物2-1的合成方法,将中间体8.7替换为8.9得到化合物2-3为淡黄色固体。m/z:[M+H]+383.0;1H NMR(400MHz,DMSO-d6):δ12.10(br.s,1H),9.76(br.s,1H),8.39(s,1H),7.88(s,1H),7.51(s,1H),7.35(s,1H),7.12(s,1H),7.01(s,1H),6.87(s,1H),1.77-1.49(m,8H),1.43-1.25(m,2H).
实施例57:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-1'H-螺[环丁烷-1,2'-吡啶并[2,3-d]嘧啶]-4'(3'H)-酮盐酸盐(化合物2-4)的合成
利用化合物2-1的合成方法,将中间体8.7替换为8.10得到化合物2-4为淡黄色固体。m/z:[M+H]+322.0.
实施例58:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-1'H-螺[环丁烷-1,2'-吡啶并[2,3-d]嘧啶]-4'(3'H)-酮盐酸盐(化合物2-5)的合成
利用化合物2-1的合成方法,将中间体8.7替换为8.11得到化合物2-5为淡黄色固体。m/z:[M+H]+385.0;1H NMR(400MHz,DMSO-d6):δ12.20(br.s,1H),9.97(br.s,1H),8.41(s,1H),8.16(s,1H),7.51(s,1H),7.37(s,1H),7.24(s,1H),7.15(s,1H),6.90(s,1H),3.70(overlapping with solvent,4H),1.91-1.66(m,4H).
实施例59:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-8'-甲氧基-1',5'-二甲基-1'H-螺[环戊烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-6)的合成
将中间体8.1(75mg,0.22mmol),7H-吡咯并[2,3-d]嘧啶-4-胺(44mg,0.33mmol)、Pd2(dba)3(20mg)、Xantphos(20mg)、Xphos(20mg)、Cs2CO3(86mg,0.26mmol)和1,4-二氧六环(3mL)的混合物置于微波反应管中,鼓吹氮气5分钟,然后微波120℃下反应8小时。将反应液减压浓缩,残留物用prep-HPLC(分离条件3)纯化得到化合物2-6(15mg,产率:17%)为类白色固体。m/z:[M+H]+393.0;1H NMR(400MHz,DMSO-d6):δ12.97(s,1H),11.63(br.s,1H),8.37(s,1H),8.32(s,1H),7.50(s,1H),7.09(s,1H),6.96(br.s,1H),3.69(s,3H),2.66(s,3H),2.57(s,3H),2.00-1.60(m,8H).
实施例60:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-8'-甲氧基-1',5'-二甲基-1'H-螺[环丁烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-7)的合成
利用化合物2-6的合成方法,将中间体8.0替换为8.2得到化合物2-7为棕色固体。m/z:[M+H]+379.0;1H NMR(400MHz,DMSO-d6):δ12.97(s,1H),11.66(s,1H),8.70(s,1H),8.33(s,1H),7.51(s,1H),7.11(s,1H),6.98(s,1H),3.75(s,3H),2.61(s,3H),2.57(s,3H),2.29-2.21(m,2H),2.14-2.05(m,2H),1.88-1.65(m,2H).
实施例61:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-8'-甲氧基-1',5'-二甲基-1'H-螺[环己烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-8)的合成
利用化合物2-6的合成方法,将中间体8.0替换为8.3得到化合物2-8为类棕色固体。m/z:[M+H]+407.0;1H NMR(400MHz,DMSO-d6):δ12.92(s,1H),11.45(s,1H),8.32(s,1H),8.11(s,1H),7.51(s,1H),7.10(s,1H),6.92(s,1H),3.73(s,3H),2.64(s,3H),2.58(s,3H),1.83(s,2H),1.65-1.30(m,8H).
实施例62:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-8'-甲氧基-1'-甲基-1'H-螺[环丁烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-9)的合成
利用化合物2-6的合成方法,将中间体8.0替换为8.5得到化合物2-9为类白色固体。m/z:[M+H]+399.0;1H NMR(400MHz,DMSO-d6):δ12.62(br.s,1H),10.67(br.s,1H),8.84(s,1H),8.38(s,1H),7.75(br.s,1H),7.48(s,1H),6.96(s,1H),3.81(s,3H),2.63(s,3H),2.30-2.20(m,2H),2.16-2.04(m,2H),1.90-1.69(m,2H).
实施例63:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-1'-甲基-1'H-螺[环戊烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-10)的合成
利用化合物2-6的合成方法,将中间体8.0替换为8.7得到化合物2-10为淡黄色固体。m/z:[M+H]+383.0;1H NMR(400MHz,DMSO-d6):δ12.20(br.s,1H),10.03(br.s,1H),8.41(s,1H),8.32(s,1H),7.59(s,1H),7.41-7.31(m,2H),6.90(s,1H),2.81(s,3H),2.00-1.90(m,2H),1.88-1.77(m,2H),1.76-1.55(m,4H).
实施例64:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-5'-氯-1'-甲基-1'H-螺[环丁烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-11)的合成
利用化合物2-6的合成方法,将中间体8.0替换为8.8得到化合物2-11为黄色固体。m/z:[M+H]+369.0;1H NMR(400MHz,DMSO-d6):δ12.15(br.s,1H),9.91(br.s,1H),8.79(s,1H),8.42(s,1H),7.65(s,1H),7.47-7.32(m,2H),6.88(s,1H),2.94(s,3H),2.48-2.43(m,2H),2.21-2.10(m,2H),1.85-1.60(m,2H).
实施例65:7'-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-1',5'-二甲基-1'H-螺[环丁烷-1,2'-吡啶[2,3-d]嘧啶]-4'(3'H)-酮盐酸盐(化合物2-12)的合成
利用化合物2-6的合成方法,将中间体8.0替换为8.12得到化合物2-12为黄色固体。m/z:[M+H]+350.0.
实施例66:2-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-6a-甲基-6a,7,8,9-四氢吡啶并[3,2-e]吡咯并[1,2-a]嘧啶-5(6H)-酮盐酸盐(化合物2-13)的合成和实施例67:2-(4-氨基-7H-吡咯并[2,3-d]嘧啶-7-基)-6a-甲基-6a,7,8,9-四氢吡啶并[3,2-e]吡咯并[1,2-a]嘧啶-5(6H)-酮盐酸盐(化合物2-14)的合成
步骤1:将2-氨基-6-氯烟酰胺(70mg,0.4mmol)和5-氯-2-戊酮(150mg,1.22mmol)的无水乙醇溶液(5mL)加热至95℃,然后缓慢滴加浓硫酸(3滴)。加毕,反应体系在95℃下搅拌过夜。将反应液倒入冰水中,有固体析出,搅拌5分钟,过滤。滤饼用石油醚洗涤,真空干燥后得到2-氯-6a-甲基-6a,7,8,9-四氢吡啶并[3,2-e]吡咯并[1,2-a]嘧啶-5(6H)-酮(60mg,产率:62%)为浅黄色固体。m/z:[M+H]+238.0;1H NMR(400MHz,DMSO-d6):δ8.66(s,1H),7.89(d,J=8.0Hz,1H),6.71(d,J=8.0Hz,1H),3.61-3.50(m,2H),2.15-1.92(m,4H),1.32(s,3H).
步骤2:将步骤1所得产物(60mg,0.25mmol),7H-吡咯并[2,3-d]嘧啶-4-胺(37mg,0.28mmol)、Cs2CO3(99mg,0.3mmol),Pd2(dba)3(23mg,0.025mmol),XPhos(12mg,0.025mmol)、XantPhos(15mg,0.025mmol)和1,4-二氧六环(3mL)的混合物用氮气吹扫后于100℃微波反应2小时。待冷至室温,过滤,滤饼用DCM/MeOH(10/1)洗涤。合并有机相,减压浓缩。残留物经prep-HPLC(分离条件6)纯化得到化合物2-13(12.8mg,产率:15%)和2-14(5.8mg,产率:7%),均为浅黄色固体。化合物2-13:UPLC RT=2.970min;m/z:[M+H]+336.0;1H NMR(400MHz,DMSO-d6):δ13.10(s,1H),12.39(br.s,1H),8.84(s,1H),8.61(s,1H),8.08(d,J=8.0Hz,1H),7.68(s,1H),7.39(s,1H),6.91(s,1H),3.97-3.87(m,1H),3.87-3.75(m,1H),2.23-2.02(m,4H),1.39(s,3H).化合物2-14:UPLC RT=3.501min;m/z:[M+H]+336.0;1HNMR(400MHz,DMSO-d6):δ9.37(br.s,2H),8.65(s,1H),8.52(s,1H),8.25(s,1H),8.15(d,J=8.0Hz,1H),7.84(d,J=8.0Hz,1H),7.16(s,1H),3.73-3.64(m,2H),2.20-1.96(m,4H),1.37(s,3H).
实施例68:8-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-6-氯-3a-甲基-2,3,3a,4-四氢吡咯并[1,2-a]喹唑啉-5(1H)-酮盐酸盐(化合物2-15)的合成
利用化合物2-13的合成方法,将2-氨基-6-氯烟酰胺替换为2-氨基-4-溴-6-氯苯甲酰胺得到化合物2-15为黄色固体。m/z:[M+H]+369.0;1H NMR(400MHz,DMSO-d6):δ12.08(br.s,1H),9.77(br.s,1H),8.39(s,1H),8.29(s,1H),7.42(s,1H),7.35(s,1H),7.23(s,1H),6.87(s,1H),3.46-3.41(m,2H),2.14-1.95(m,4H),1.27(s,3H).
实施例69:9-((7H-吡咯并[2,3-d]嘧啶-4-基)氨基)-7-氯-4a-甲基-3,4,4a,5-四氢-1H-吡啶并[1,2-a]喹唑啉-6(2H)-酮盐酸盐(化合物2-16)的合成
利用化合物2-13的合成方法,用2-氨基-4-溴-6-氯苯甲酰胺和6-氯-2-己酮反应得到化合物2-16为黄色固体。m/z:[M+H]+383.0;1H NMR(400MHz,DMSO-d6):δ12.10(br.s,1H),9.82(br.s,1H),8.40(s,1H),8.23(s,1H),7.66(s,1H),7.41-7.32(m,2H),6.86(s,1H),2.77-2.69(m,1H),2.57-2.53(m,1H),1.91-1.79(m,2H),1.76-1.44(m,4H),1.24(s,3H).
实施例70:8-((7H-吡咯[2,3-d]嘧啶-4-基)氨基)-9-甲氧基-3a,6-二甲基-2,3,3a,4-四氢吡咯并[1,2-a]喹唑啉-5(1H)-酮盐酸盐(化合物2-17)的合成
利用化合物2-13的合成方法,将2-氨基-6-氯烟酰胺替换为2-氨基-4-溴-3-甲氧基-6-甲基苯甲酰胺得到化合物2-17为黄色固体。m/z:[M+H]+379.0;1H NMR(400MHz,DMSO-d6):δ12.91(s,1H),11.50(br.s,1H),8.30(s,1H),8.12(s,1H),7.51(s,1H),6.97(s,1H),6.88(s,1H),3.73-3.68(m,1H),3.50(overlapping with the solvent,3H),3.36-3.29(m,1H),2.59(s,3H),2.29-2.18(m,1H),2.03-1.84(m,3H),1.37(s,3H).
实施例71:9-((7H-吡咯[2,3-d]嘧啶-4-基)氨基)-10-甲氧基-4a,7-二甲基-3,4,4a,5-四氢-1H-吡啶并[1,2-a]喹唑啉-6(2H)-酮盐酸盐(化合物2-18)的合成
利用化合物2-13的合成方法,用2-氨基-4-溴-3-甲氧基-6-甲基苯甲酰胺和6-氯-2-己酮反应得到化合物2-18为黄色固体。m/z:[M+H]+393.0;1H NMR(400MHz,DMSO-d6):δ12.91(s,1H),11.33(s,1H),8.33(s,1H),8.23(s,1H),7.51(s,1H),7.19(s,1H),6.85(s,1H),3.76(s,3H),3.70-3.65(m,1H),3.15-3.05(m,1H),2.60(s,3H),2.02-1.91(m,1H),1.74-1.45(m,5H),1.25(s,3H).
实施例72:7'-((6-氨基嘧啶-4-基)氨基)-5'-氯-1'-甲基-1'H-螺[环丁烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-19)的合成
利用化合物1-1的合成方法,将中间体1.1替换为8.15得到化合物2-19为黄色固体。m/z:[M+H]+345.0;1H NMR(400MHz,DMSO-d6):δ10.69(s,1H),8.82(s,1H),8.50(s,1H),8.12(br.s,2H),7.22(s,1H),7.02(s,1H),6.24(s,1H),2.91(s,3H),2.46(overlappingwith the solvent,2H),2.22-2.04(m,2H),1.84-1.61(m,2H).
实施例73:7'-((7H-吡咯[2,3-d]嘧啶-4-基)氨基)-1',5'-二甲基-1'H-螺[环丁烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-20)的合成
利用化合物2-6的合成方法,将中间体8.0替换为8.13得到化合物2-20为淡黄色固体。m/z:[M+H]+349.0;1H NMR(400MHz,DMSO-d6):δ12.79(s,1H),11.20(br.s,1H),8.72(s,1H),8.38(s,1H),7.49(s,1H),7.06(s,1H),7.01(s,1H),6.92(s,1H),3.93-3.83(m,1H),2.90(s,3H),2.81(d,J=8.0Hz,1H),2.60(s,3H),2.23-2.10(br.s,2H),1.86-1.73(m,1H),1.74-1.61(m,1H).
实施例74:7'-((7H-吡咯[2,3-d]嘧啶-4-基)氨基)-5'-氯-8'-氟-1'-甲基-1'H-螺[环丁烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-21)的合成
利用化合物2-6的合成方法,将中间体8.0替换为8.14得到化合物2-21为黄色固体。m/z:[M+H]+387.0;1H NMR(400MHz,DMSO-d6):δ12.30(br.s,1H),10.16(br.s,1H),8.91(s,1H),8.37(s,1H),7.86(d,J=5.6Hz,1H),7.41(s,1H),6.89(s,1H),2.63(s,3H),2.29-2.17(m,2H),2.15-2.04(m,2H),1.91-1.68(m,2H).
实施例75:7'-((6-氨基嘧啶-4-基)氨基)-5'-氯-8'-氟-1'-甲基-1'H-螺[环丁烷-1,2'-喹唑啉]-4'(3'H)-酮盐酸盐(化合物2-22)的合成
利用化合物1-1的合成方法,将中间体1.1替换为8.16得到化合物2-22为黄色固体。m/z:[M+H]+362.8;1H NMR(400MHz,DMSO-d6):δ10.07(br.s,1H),8.85(s,1H),8.38(s,1H),8.07-7.35(m,3H),6.08(s,1H),2.61(s,3H),2.26-2.16(m,2H),2.12-2.02(m,2H),1.90-1.67(m,2H).
生物实施例
实施例1:MNK1和MNK2体外酶抑制水平测试
本实验使用ADP-GloTMMax Assay Kit(Promega,V9101)检测反应ADP的生成量以计算化合物对酶的抑制率。实验使用的缓冲液成分为:15mM HEPES,10mM MgCl2,20mM NaCl,1mM EGTA,0.1mg/ml牛血清蛋白,0.02%Tween-20。MNK1反应体系包括20nM MNK1(Thermo,PR9138A),100uM多肽(吉尔生化,序列:Ac-TATKSGSTTKNR-NH2),200uM ATP和不同浓度的待测化合物,DMSO的终浓度为0.33%,反应体系在室温条件下孵育60分钟。MNK2反应体系包括5nM MNK2(Thermo,PR8046A),100uM多肽(吉尔生化,序列:Ac-TATKSGSTTKNR-NH2),100uMATP和不同浓度的待测化合物,DMSO的终浓度为0.33%。反应体系在室温条件下孵育45分钟。孵育完成后使用ADP-GloTMMax Assay Kit检测产生的ADP并使用TECAN M1000-pro检测。实验数据通过GraphPad Prism 5软件进行分析处理以得出IC50值。
表6
实施例2:pEIF4E细胞水平检测
通过磷酸化真核起始因子eIF4E及其他关键效应蛋白,激酶MNK1和MNK2整合了几种致癌因子和免疫信号通路,从而选择性调控细胞mRNA的稳定性和转录。
Phospho-EIF4E(Ser209)cellular assay试剂盒(Cisibo)用于测定OCI-LY7 B细胞非霍奇淋巴瘤细胞中内源性EIF4E的磷酸化水平。该实验是根据制造商的实验方案进行的。简单来说,OCI-LY7细胞用50uL的2×106细胞/毫升的无血清IMDM培养基铺在96孔细胞培养板上,并在37℃培养过夜。次日,待测化合物的浓度范围是通过稀释100%DMSO,然后进一步用无血清培养基稀释来创建的。细胞加入稀释的化合物并在37℃培养3h。然后向细胞中加入4X的细胞裂解液,室温振荡30分钟。取16uL的裂解液转移至384白色浅孔板,然后加入4uL预配制的抗体混合溶液,1000rpm离心30s。用封板膜封板,室温孵育过夜。然后在TECAN M1000 Pro读板仪上使用HTRF设置进行测试。结果如下表7:
表7
编号 | IC<sub>50</sub>(nM) | 编号 | IC<sub>50</sub>(nM) |
1-3 | 5.132 | 1-38B | 1.250 |
1-4 | 3.610 | 2-2 | 2.321 |
1-6 | 2.179 | 2-9 | 1.600 |
1-9 | 2.600 | 2-11 | 0.479 |
1-12 | 1.556 | 2-15 | 0.731 |
1-16 | 1.588 | 2-19 | 3.195 |
1-28 | 1.574 | 2-20 | 4.822 |
1-28B | 0.690 | 2-21 | 0.682 |
1-38 | 1.410 | 2-22 | 0.934 |
Claims (17)
1.一种如式I或I’所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐;
其中,W1和W2分别独立地为=O、=S、=NH、=N-OH或=N-O(C1-6烷基);
A1为N或CR5;
A2为N或CR5a;
A3为N或CR5b;
R为-NH-Cy或Cy;
R1为H、-OH、-NH2、RA、-NH-RA、-NH-C(O)-RA或-O-RA;
R2为H、CN、氘代C1-4烷基或RB;
R3为H、C1-6烷基、C2-6烯基或C2-6炔基;所述R3为未取代,或者选择性被1~3个R9取代在任意位置;
R4为H、C1-6烷基、C2-6烯基、C2-6炔基、C6-10芳基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、C6-10芳基C1-6烷基、5-6元杂芳基C1-6烷基、C3-8环烷基C1-6烷基或3-8元杂环烷基C1-6烷基;所述R4为未取代,或者选择性被1~3个R9取代在任意位置;
所述R1、R2、R3和R4分别为独立取代基,或者
1)R1和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
2)R2和R3相互连接形成3-10元杂环烷基;所述3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
3)R3和R4与其共同连接的碳原子一起形成C3-10环烷基或3-10元杂环烷基;所述C3-10环烷基或3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;或
4)R2和R3相互连接与α键共同形成双键;
R5、R5a和R5b分别独立地为氢、卤素、氰基、C1-4烷基、卤代C1-4烷基、卤代C1-4烷氧基或C1-4烷氨基;
Cy为5-10元杂芳环;所述Cy为未取代,或者选择性被1~3个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC、-C(O)RC和-C(O)N(RC)2的取代基取代在任意位置;
每个RA独立地为C1-8烷基、C2-8烯基或C2-8炔基;所述RA为未取代,或者选择性被1~3个选自卤素、-OH、-NH2、氧代基、C1-3烷氧基和C1-3烷氨基的取代基取代在任意位置;
每个RB独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基或-(CH2)n-(3-8元杂环烷基);所述RB为未取代,或者选择性被1~3个R9取代在任意位置;
每个RC独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基、-(CH2)n-(3-8元杂环烷基)或-(3-8元杂环烷基)-C1-6烷基;所述RC为未取代,或者选择性被1~3个R10取代在任意位置;
每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、-C(O)Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基、卤代C1-4烷氧基、-(CH2)n-NH2、-(CH2)n-OH、-(CH2)n-(C1-4烷氨基)或-(CH2)n-(C1-4烷氧基);
每个Ra独立地为C1-6烷基或C2-6烯基;
n为1、2、3或4。
3.如权利要求2所述的如式I或I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,其特征在于,R6为H、F、Cl、-CN、-NH2、-CH3、-CF3、-CH2CH3、-OCH3、-OCH2CH3、-OCF3、-O-正丙基、-O-异丙基、环丙基或1-甲基-1H-吡唑基;
和/或,R7为H、-NH2、-NHRC、-NH-ORC或-NHC(O)RC;
和/或,R8为H。
5.如权利要求4所述的如式I或I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,其特征在于,R8为H;
和/或,R11为H;
和/或,R12为H。
6.如权利要求1所述的如式I或I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,其特征在于,R9为H、-NH2、-OH、F、Cl、=O、-NHC(O)-C2-6烯基、-C(O)-C2-6烯基、-NHS(O)2-C2-6烯基、C1-4烷基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基。
7.如权利要求1所述的如式I或I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,其特征在于,W1为O;W2为O;
和/或,R1为H、-OH、-OCH3、-NH2、-NH(CH3)、-NH(CH2CH3)或-NH(CH2CH=CH2);
和/或,R2为H、CD3、C1-6烷基、C2-6烯基、苯基、或5-6元杂芳基;所述R2为未取代,或者选择性被1~3个选自F、Cl、-OH、-NH2、=O、-OCH3、-N(CH3)2和-NHC(O)CH=CH2的取代基取代在任意位置;
和/或,R3为H、甲基或乙基;
和/或,R4为甲基、乙基、正丙基、异丙基、苯基、吡啶基、环丙基、环丁基、环戊基或环己基;所述R4为未取代,或者选择性被1~2个或1个选自氟、氯、甲基和三氟甲基的取代基取代在任意位置;
和/或,R5为氢、卤素或C1-4烷基;
和/或,R5a为H;
和/或,R5b为氢、卤素、C1-4烷氧基或C1-4烷基。
8.如权利要求1所述的如式I或I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,其特征在于,R3和R4与其共同连接的碳原子一起形成环丙基、环丁基、环戊基、环己基、2,3-二氢-1H-茚基、2,3-二氢-1H-茚基-1-酮、螺[3,2]己基、螺[3.3]庚基、四氢呋喃基、吡咯烷基、氮杂环丁基、哌啶基或1-氧代-硫杂环丁基;
或,R2和R3相互连接形成5-6元杂环烷基;所述5-6元杂环烷基为未取代,或者选择性被1个=O取代在任意位置。
9.如权利要求1所述的如式I或I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,其特征在于,所述如式I或I’所示的化合物为式II所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,
其中,R1为H、-OH、-NH2、RA、-NH-RA、-NH-C(O)-RA或-O-RA;
R2为H、CN或RB;
R3为H、C1-6烷基、C2-6烯基或C2-6炔基;所述R3为未取代,或者选择性被1~3个R9取代在任意位置;
R4为H、C1-6烷基、C2-6烯基、C2-6炔基、C6-10芳基、5-6元杂芳基、C3-8环烷基或3-8元杂环烷基;所述R4为未取代,或者选择性被1~3个R9取代在任意位置;
所述R3和R4为独立取代基,或者R3和R4与其共同连接的碳原子一起形成C3-10环烷基或3-10元杂环烷基;所述C3-10环烷基或3-10元杂环烷基为未取代,或者选择性被1~3个R9取代在任意位置;
R5为氢、卤素、氰基或C1-4烷基;
R6、R7和R8分别独立地为H、卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC或-NHS(O)2RC;
R6和R7分别为独立取代基,或者R6和R7与其连接的原子一起形成杂芳基或杂环烷基;所述杂芳基或杂环烷基为未取代,或者选择性被1~3个选自卤素、-CN、-NH2、-NHOH、-OH、-RC、-ORC、-NHRC、-NH-ORC、-NHC(O)RC、-C(O)RC和-C(O)N(RC)2的取代基取代在任意位置;
每个RA独立地为C1-8烷基、C2-8烯基或C2-8炔基;所述RA为未取代,或者选择性被1~3个选自卤素、-OH、-NH2、氧代基、C1-3烷氧基和C1-3烷氨基的取代基取代在任意位置;
每个RB独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基或-(CH2)n-(3-8元杂环烷基);所述RB为未取代,或者选择性被1~3个R9取代在任意位置;
每个RC独立地为C1-6烷基、C2-6烯基、C2-6炔基、苯基、5-6元杂芳基、C3-8环烷基、3-8元杂环烷基、-(CH2)n-OC1-6烷基、-(CH2)n-苯基、-(CH2)n-(5-6元杂芳基)、-(CH2)n-C3-8环烷基、-(CH2)n-(3-8元杂环烷基)或-(3-8元杂环烷基)-C1-6烷基;所述RC为未取代,或者选择性被1~3个R10取代在任意位置;
每个R9和每个R10分别独立地为H、-CN、-NO2、-SH、-NH2、-OH、-C(O)OH、-NHC(O)Ra、-NHS(O)2Ra、-C(O)Ra、卤素、氧代基、酯基、酰胺基、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C1-4烷氨基、卤代C1-4烷基或卤代C1-4烷氧基;
每个Ra独立地为C1-6烷基或C2-6烯基;
n为1、2、3或4。
10.如权利要求1~6任一项所述的如式I或I’所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,其特征在于,所述如式I或I’所示的化合物为式IV、V、VI、VII或VIII所示的化合物,其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,
通式IV所示的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
R1、R2、R5、R6、R7、R8和R9的定义如权利要求1~6任一项所述;
通式V所示的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
R1、R4、R5、R6、R7、R8和R9的定义如权利要求1~6任一项所述;
通式VI所示的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,R1、R4、R5、R6、R7和R8的定义如权利要求1~6任一项所述;
通式VII所示的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
R1、R2、R5、R6、R7、R8、R9和A3的定义如权利要求1~6任一项所述;
通式VIII所示的化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐:
其中,m为0、1、2或3;t为0、1、2或3;
R1、R4、R5、R6、R7、R8、R9和A3的定义如权利要求1~6任一项所述。
12.一种药物组合物,其包括活性组分以及药学上可接受的辅料;所述活性组分包括如权利要求1~11任一项所述的如式I或I’所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐。
13.如权利要求12所述的药物组合物,其进一步还包含其它种类的用于治疗由于MNK1和/或MNK2水平失常引起的相关疾病的治疗剂。
14.如权利要求13所述的药物组合物,其特征在于,所述的由MNK1和/或MNK2水平失常引起的相关疾病为癌症。
15.一种如权利要求1~11任一项所述的如式I或I’所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,或如权利要求12所述药物组合物在制备MNK1和/或MNK2抑制剂药物中的应用。
16.一种如权利要求1~11任一项所述的如式I或I’所示化合物、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐,或如权利要求12和13所述药物组合物在制备治疗和/或缓解由MNK1和/或MNK2水平失常引起的相关疾病的药物中的应用。
17.如权利要求16所述的应用,其特征在于,所述的由MNK1和/或MNK2水平失常引起的相关疾病为癌症。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811454361 | 2018-11-30 | ||
CN2018114543618 | 2018-11-30 | ||
CN201910018886 | 2019-01-09 | ||
CN2019100188865 | 2019-01-09 | ||
CN201910089611 | 2019-01-30 | ||
CN2019100896110 | 2019-01-30 | ||
CN2019102706572 | 2019-04-04 | ||
CN201910270657 | 2019-04-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111253397A true CN111253397A (zh) | 2020-06-09 |
CN111253397B CN111253397B (zh) | 2023-11-14 |
Family
ID=70852650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911196669.1A Active CN111253397B (zh) | 2018-11-30 | 2019-11-29 | Mnk抑制剂 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111253397B (zh) |
WO (1) | WO2020108619A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111848527A (zh) * | 2020-08-11 | 2020-10-30 | 南通大学 | 一种4-氯-2-(2-氟-4-甲氧基苯基)-6-甲氧基喹唑啉及其合成方法 |
WO2022222871A1 (en) * | 2021-04-21 | 2022-10-27 | Beijing Innocare Pharma Tech Co., Ltd. | Heterocyclic compounds as kras g12c inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114539080A (zh) * | 2022-03-02 | 2022-05-27 | 八叶草健康产业研究院(厦门)有限公司 | 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108602814A (zh) * | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | 抑制mnk1和mnk2的吡咯并-、吡唑并-、咪唑并-嘧啶和吡啶化合物 |
CN108602805A (zh) * | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1149762A (ja) * | 1997-08-08 | 1999-02-23 | Japan Tobacco Inc | チアゾール化合物 |
AU2014211728B2 (en) * | 2013-02-04 | 2018-05-17 | Merck Patent Gmbh | Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions |
WO2015146928A1 (ja) * | 2014-03-24 | 2015-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
-
2019
- 2019-11-29 CN CN201911196669.1A patent/CN111253397B/zh active Active
- 2019-11-29 WO PCT/CN2019/121976 patent/WO2020108619A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108602814A (zh) * | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | 抑制mnk1和mnk2的吡咯并-、吡唑并-、咪唑并-嘧啶和吡啶化合物 |
CN108602805A (zh) * | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111848527A (zh) * | 2020-08-11 | 2020-10-30 | 南通大学 | 一种4-氯-2-(2-氟-4-甲氧基苯基)-6-甲氧基喹唑啉及其合成方法 |
WO2022222871A1 (en) * | 2021-04-21 | 2022-10-27 | Beijing Innocare Pharma Tech Co., Ltd. | Heterocyclic compounds as kras g12c inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2020108619A1 (zh) | 2020-06-04 |
CN111253397B (zh) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104884458B (zh) | 作为蛋白质激酶抑制剂的稠合杂环化合物 | |
CN109311843B (zh) | 作为PI3Kβ抑制剂的氮杂苯并咪唑衍生物 | |
JP5129812B2 (ja) | ビシクロアニリン誘導体 | |
KR101961500B1 (ko) | 세린/트레오닌 키나제 억제제 | |
CA2800079C (en) | Macrocyclic compounds as trk kinase inhibitors | |
AU2019205984A1 (en) | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo [3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins | |
WO2019037678A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
CN113666923A (zh) | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 | |
EP3604306A1 (en) | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | |
JP6936820B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤としてのアザデカリン誘導体 | |
CN111253397B (zh) | Mnk抑制剂 | |
US20220213112A1 (en) | Pyrrole tricyclic compounds as a2a / a2b inhibitors | |
EP3694330B1 (en) | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
JP2022522534A (ja) | Prmt5を標的にする化合物 | |
CA3145348A1 (en) | Pyrazolone and pyrimidine compound, and preparation method and use therefor | |
EP4074710A1 (en) | Pyrazolo[1,5-a]pyridine compound, preparation method therefor and use thereof | |
WO2020103897A1 (zh) | 杂环稠合嘧啶衍生物、其药物组合物及应用 | |
CN112094269B (zh) | 一类饱和六元环并杂环类化合物、制备方法和用途 | |
CN114746414A (zh) | 氮杂-喹啉化合物及其用途 | |
JP7436465B2 (ja) | 毛細血管拡張性運動失調症変異(ATM)キナーゼの選択的調節物質としての1-イソプロピル-3-メチル-8-(ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オンおよびその使用 | |
CN112442050A (zh) | 一种ret抑制剂、其药物组合物及其用途 | |
CN117377675A (zh) | 含有并环或螺环的布鲁顿酪氨酸激酶降解剂 | |
CN113045569B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
TW202400581A (zh) | 驅動蛋白kif18a抑制劑及其應用 | |
US10550125B2 (en) | Prodrugs of imidazotriazine compounds as CK2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |